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ABSTRACT 
 
Vomiting is a frequent postoperative complication in children receiving general 
anesthesia, with reported incidences of 8.9 to 42%, and is the fourth most common indication for 
unexpected hospital admission. Intravenous fluids containing dextrose are commonly used in 
children.  Although studies using these intravenous fluids in the perioperative period have shown 
improvement in the postoperative recovery, including reducing the incidence of postoperative 
vomiting in adults, similar studies have not been done in pediatric patients.   
In this dissertation, I have described the efficacy of intraoperative intravenous dextrose 
compared to ondansetron as a prophylactic antiemetic in children undergoing ambulatory dental 
procedures under general anesthesia. 
A double-blinded randomized control trial was conducted of 300 healthy children, aged 3 
to 9 years without known risk factors for postoperative vomiting, who underwent ambulatory 
dental procedures under general anesthesia. Patients were randomized into two groups based on 
antiemetic prophylaxis. The control group received dexamethasone (0.15 mg/kg IV) and 
ondansetron (0.05 mg/kg IV); the intervention group received dexamethasone (0.15 mg/kg IV) 
and intravenous 5% Dextrose in 0.9% normal saline maintenance fluid. The approach used to 
analyze the data was based on an intention to treat analysis. The primary outcome, emesis in the 
post-anaesthetic care unit within 2 hours after surgery, was compared using Chi-Square. The 
secondary outcomes were analysed by T-test and non-parametric analysis when appropriate. A 
non-inferiority analysis of intraoperative intravenous dextrose relative to ondansetron was 
conducted with δ = 7.5 % as the non-inferiority limit. 
290 patients were analyzed (intervention group N=144, control group N=146). 
Demographics and intraoperative anaesthetic management were similar between groups. Emesis 
in PACU was also similar between groups. Emesis in the post-anesthetic care unit was not 
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significantly different between groups (p = 0.11) with a postoperative vomiting proportion of 
7.64 % and 3.45% for the intervention and control groups respectively, and a proportion 
difference of 4.2% (CI 95%   -1.0, 9.5). The results of this study were inconclusive in 
demonstrating that intravenous dextrose is not less effective than ondansetron in preventing 
postoperative vomiting.  
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CHAPTER 1 
INTRODUCTION 
 
1.1.Thesis structure 
 
This thesis contains five chapters. This chapter introduces the problem of postoperative 
nausea and vomiting and provides a brief review of the possible solutions. Chapter Two reviews 
the literature on the pathophysiology of nausea and vomiting, the prevention of these 
complications in the postoperative period and different strategies and guidelines to address this 
problem. Chapter Three presents an overview of the design and methodologies used in the 
randomized control trial conducted and gives a description of the test statistics employed for the 
analysis of the data. Chapter Four presents the results of the study and analysis of the data. 
Chapter Five contains the main findings of the study, the discussion and conclusions.  
 
1.2.Background 
 
One of the most frequently encountered complications following surgical procedures, 
especially those performed under general anesthesia is postoperative nausea and vomiting 
(PONV), causing morbidity and dissatisfaction among adult and pediatric patients  (Baines, 1996; 
Longnecker, Brown, Newman, & Zapol, 2011). Along with postoperative pain and behavioural 
disturbances, PONV is the most common reason for inpatient admission following ambulatory 
surgery  (Shnaider & Chung, 2006). This finding was confirmed in a review of 10772 pediatric 
patients who underwent day surgery (Awad et al., 2004). This study found that after pain, 
surgical complications and surgery late in the day, PONV was the fourth most common cause of 
unexpected hospital admission.  
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Studies of PONV have been conducted on adult populations more often than on pediatric 
patients even though it has been estimated that the overall incidence of nausea and vomiting after 
surgery in children is twice that of adults.  The incidence of PONV in children is reported to be 
between 8.9 and 42% of all pediatric surgical cases and up to 80% of cases of surgery-specific 
postoperative vomiting (POV) (Gan et al., 2014; Kovac, 2007). This high incidence of POV may 
be associated with the inability of young children to communicate the sensation of nausea, which 
they may experience either in the post-anesthetic care unit or at home after discharge (Kotiniemi 
et al., 1997). PONV can lead to numerous complications, including dehydration, electrolyte 
abnormalities, suture dehiscence, bleeding and life-threatening airway compromise, resulting in 
possible detrimental long-term effects  (Apfel et al., 2002; Scuderi & Conlay, 2003). Given these 
potentially serious complications, preventing PONV before, during and immediately after surgery 
is important. 
 
A number of guidelines have been published on the management of PONV, including the 
prophylactic administration of pharmacologic antiemetic therapies in both adults and children 
(American Society of Anesthesiologists., 2013; Gan et al., 2003; Gan, Meyer et al., 2007; Gan et 
al., 2014). Among other pharmacologic antiemetic therapies, the administration of dextrose-
containing solutions has recently been highlighted as a potential intervention for decreasing the 
incidence of PONV and improving recovery in ambulatory surgery patients (Dabu-Bondoc et al., 
2013; Patel et al., 2013). One theory for the effectiveness of dextrose is its effect on muscle 
contraction in the gastrointestinal tract  (Russo, Fraser, & Horowitz, 1996). It is thought that 
dextrose given orally creates high osmotic pressure, which acts directly on the bowel wall (Dabu-
Bondoc et al., 2013), but the exact mechanism of action is unclear. In a review, Reid et al. (2009) 
discussed the use of dextrose intravenously as a potential therapy that may help to rehydrate 
children with a deficit secondary to acute gastroenteritis.  
 
The theory behind the rehydration of children suggests that a lack of carbohydrate intake 
secondary to persistent emesis leads to free fatty acid breakdown and ketone surplus, which 
results in a ketoacidosis state and a perpetual cycle of nausea and vomiting  (Reid & Losek, 
2009). The administration of intravenous dextrose stimulates insulin release, reducing free fatty 
acid breakdown and ketosis and, in turn, decreases nausea and vomiting  (Levy & Bachur, 2007). 
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Although patients undergoing surgery are not acutely ill with gastrointestinal disease, they are 
fasting with a reduced carbohydrate intake in the preoperative period. 
 
Studies examining the effects of oral dextrose being loaded preoperatively in pediatric 
patients show an association between the oral administration of simple sugar and a reduction in 
PONV (Hausel, Nygren, Thorell, Lagerkranser, & Ljungqvist, 2005). In children, ingestion of 
sugar containing liquids prior to surgery may be potentially difficult because they arrive in the 
holding area anxious, fasting and fearful.  
 
A number of studies in adults have been done to assess the role of dextrose on reducing 
postoperative nausea and vomiting. One of these studies indicated that postoperative intravenous 
dextrose administration results in decreased rates of antiemetic administration and PACU length 
of stay, but with no significant difference in the incidence of postoperative nausea and vomiting 
(Dabu-Bondoc et al., 2013). Another study considered the same population and the same 
outcomes but using intra-operative rather than post-operative intravenous dextrose containing 
solutions. Again, results showed no significant difference between the intervention and control 
group in the incidence of PONV (Patel et al., 2013). 
 
Although several studies have been conducted on preventing PONV in adults, few have 
investigated the use of intravenous interventions used in the pediatric population  (Apfel, 
Heidrich et al., 2012; Shen, Chen, Wu, Cherng, & Tam, 2014; M. D. Smith et al., 2014).  
 
 
1.3.Hypothesis  
 
The hypothesis of this study was that administering intravenous dextrose during the 
operative period to children undergoing ambulatory dental procedures under general anesthesia 
would reduce the incidence of postoperative vomiting.  
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1.4.Purpose of the study  
 
The main purpose of this study is to investigate the efficacy of intravenous dextrose in 
preventing POV in a pediatric population undergoing dental procedures under general anesthesia 
in a surgical centre.  
 
A secondary purpose is to assess other potential benefits of dextrose, a safe intervention 
commonly used to provide maintenance fluids for pediatric patients. The potential benefits 
include improving the recovery of pediatric surgical patients undergoing same-day surgery under 
general anesthesia, reducing the amount of required rescue antiemetic medications, and 
improving patient and parent satisfaction.   
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CHAPTER 2 
LITERATURE REVIEW 
 
 This chapter explores the definition and pathophysiology of nausea and vomiting, mainly 
as a postoperative complication. Special attention is given to the significance of postoperative 
nausea and vomiting in children, methods of studying it, and the current literature on its 
management and treatment.  
  
2.1. Nausea and vomiting  
 
2.1.1. Definitions 
 
The following definitions will apply for the purpose of this thesis  (Becker, 2010; 
McCracken, Houston, & Lefebvre, 2008; Shinpo, Hirai, Maezawa, Totsuka, & Funahashi, 2012)  
 
- Nausea is a subjective feeling of the need to vomit. The nauseated patient does not 
necessarily vomit or retch.  
 
- Postoperative Nausea and Vomiting (PONV) is defined as nausea and/or vomiting 
within 24 hours after surgery. 
  
- Postoperative Vomiting (POV) is defined as vomiting within 24 hours after surgery.  
 
- Regurgitation is the effortless passage of gastric contents into the mouth.  
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- Retching is the muscular events of vomiting without expulsion of vomitus, also referred 
to by patients as “the dry heaves.”  
- Vomiting or emesis is the oral expulsion of gastrointestinal contents, as a result of 
contractions of the gut and the thoraco-abdominal wall musculature.   
 
 
2.1.2. Pathophysiology of nausea and vomiting     
 
Nausea, vomiting and, more specifically, the emetic reflex has been considered an 
essential part of the defense mechanism of the body. This mechanism includes the identification 
and removal of accidentally ingested toxins and the alert system for the presence of 
gastrointestinal irritation and centrally related stimuli or conditions, including brain tumours and 
the side effects caused by certain medications (Mitchelson, 1992; Pleuvry, 2012). Despite their 
importance in the body’s defence mechanism, nausea and vomiting are considered to be a 
significant undesirable feeling among patients, leading researchers to recognize their impact on 
patients’ wellbeing. Research has focused on understanding the mechanisms behind the 
occurrence of these conditions, and the development of new medications and strategies for their 
prevention and management.  
 
The concepts of neuroanatomical and physiological pathways associated with the process 
of vomiting are central to understanding the physiopathology of emesis in general and how 
different medications and their mechanisms of action are involved in this process.   
 
 
2.1.2.1 The neural system associated with vomiting  
 
The process of vomiting is initiated by the stimulation of a diffuse area, known as the 
vomiting center, located in the medulla oblongata within the brainstem. Initial studies performed 
by Wang and Borison in the early 1950s led to the introduction of the concept of the vomiting 
centre (Hornby, 2001). Subsequent studies using experimental animals have failed to demonstrate 
a specific “centre,” but rather identified an area called the parvicellular reticular formation, which 
contains some of the neuroanatomical connections important for the vomiting process 
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(Benarroch, 2011). Different authors have also referred to this area as a coordinated control 
system or the central pattern generator (CPG)  (Horn, Wallisch, Homanics, & Williams, 2014; A. 
D. Miller & Leslie, 1994) thus maintaining consistency with research findings that indicate a 
network of multiple neural connections that activates the neurons in appropriate sequence, 
producing a coordinated motor output translated into the act of vomiting (Hornby, 2001).  
 
The CPG receives afferent information that is integrated to generate an efferent signal, a 
process that is coordinated by the Nucleus of the Solitary Tract (NST), also located in the 
medulla oblongata. The NST has neural projections that integrate pathways, including neurons 
from the reticular formation, the respiratory center, somatic and autonomic nervous system, and 
the CPG in response to the incoming stimuli (Benarroch, 2011; Horn et al., 2014). The NST, 
along with the Area Postrema (AP) and the dorsal vagal motor nucleus (DVMN), comprises the 
so-called Dorsal Vagal Complex (DVC), the major site of afferent nerve fibres of the vagal nerve 
(Fig. 2-1) (Becker, 2010; Benarroch, 2011; Horn et al., 2014; Hornby, 2001; Mori et al., 2010).  
 
Vomiting can be triggered by the activation of five main pathways that have direct neural 
projections to the NST. The five pathways are as follows: The AP, gastrointestinal vagal afferent 
fibres, the forebrain, the vestibular region and the cerebellum (Becker, 2010; Horn et al., 2014) . 
 
The first and one of the most important areas involved in the process of vomiting is the 
AP, also know as the Chemoreceptor Trigger Zone (CTZ). The AP constitutes one of the sensory 
circumventricular organs that serve as an interface between the cerebrospinal fluid and the brain 
parenchyma.  This organ is located in the medulla oblongata along the walls of the fourth 
ventricle and receives its blood supply from the posterior inferior cerebral arteries. This area is 
characterized by lack of a blood-brain barrier, influencing the easy passage of substances present 
in the blood, regardless of their lipid solubility or molecular size (i.e. large peptides such as 
amylin), allowing irritants to be in direct contact with this chemosensitive region (Becker, 2010; 
Benarroch, 2011; Shinpo et al., 2012).  
 
The AP is interconnected to the NST and the lateral parabrachial nucleus through direct 
visceral afferent projections originated via the vagus nerve. Simultaneously, the AP has 
numerous projections to other neural structures, including the dorsal nucleus of the vagus and the 
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nucleus ambiguous for the control of gastrointestinal effectors, phonation and swallowing. The 
AP also receives different descending inputs from the paraventricular nucleus, which constitutes 
the main autonomic centers of the hypothalamus (Benarroch, 2011).  
 
Numerous receptors located in the CTZ are important for the stimulation of the NST and 
the CPG, including serotonin (5-HT3), dopamine (D2), acethylcholine (Ach), histamine (H), 
opioid (mu), cannabinoid (CB1R, CB2R), and substance P - neuro-kinin receptor (NK1) 
(Hornby, 2001; Welliver, 2013).  Animal studies have demonstrated the presence of higher 
concentrations of 5-HT3, D2 and opioid receptors more so than the other types of receptors in this 
chemosensitive region. Studies in humans have shown that the stimulation of these three specific 
receptors at the CTZ by drugs acting as agonists trigger nausea and vomiting. Similar studies 
have demonstrated the antiemetic effect of 5-HT3 and D2 receptor antagonists in the area but 
have failed to show similar antiemetic effects from opioid antagonist agents (Pleuvry, 2012).  
 
The second pathway involves the gastrointestinal (GI) tract from the esophagus to the 
ileum by the initiation of afferent impulses originated in mechanoreceptors and chemoreceptors 
along the GI tract, which sense changes in the GI wall distension and the presence of substances 
(for example, acids, alkalis, toxins and irritants) in the GI mucosa. As a result, the visceral 
information from the GI receptors, especially those from the upper GI tract, generates afferent 
impulses that are transmitted via the gastrointestinal vagal afferent fibres and the spinal afferent 
system. The vagal afferent fibres project connections to the NST and the CPG, followed by 
secondary and third-order neuronal projections, that ascend to the thalamus, hypothalamus, the 
amygdala and the sensory cortex, which in response stimulate efferent pathways to the 
anatomical areas involved in the vomiting process  (Holtmann & Talley, 2014; Pleuvry, 2012). 
The close relation of different structures to the afferent fibres of the vagal nerve supports the 
importance of the integrity of the abdominal vagus as a stimulus of the vomiting process  
(Hornby, 2001; A. D. Miller & Leslie, 1994). 
 
The efferent pathways include the cranial nerves (5th, 7th, 9th, 10th and 12th) that innervate 
the upper gastrointestinal tract; the vagal and sympathetic nerves that innervate the oesophagus 
and stomach, causing proximal relaxation; the small intestine, triggering a retrograde contraction; 
and the spinal somato-motor and phrenic motor neurons that innervate the abdominal wall 
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muscles and the diaphragm , respectively (Fig. 2-2)  (Becker, 2010; Sanger & Andrews, 2006). 
Autonomic efferents also supply innervation to other areas including the respiratory tract  
and heart (vagus), skin (sympathetic constrictors) and the salivary glands (chorda tympani), 
accounting for some of the prodromal symptoms associated with the act of vomiting  (Sanger & 
Andrews, 2006).  
 
Figure 2-1: Central Pattern Generator 
 
Fig 2-1a.    
 
  
Fig 2-1b. 
 
 
The major neurotransmitter implicated in the gastrointestinal pathway associated with the 
vomiting process is serotonin (5-HT3), a neurotransmitter released from the cells in the GI tract 
2-1a. Lateral view of the brain and the brainstem 
From “Dissected Brain Lateral View” by Alexluengo 
(image32775542#res1218957). Copyright [2017] by 
Dreamstime.com Purchased and adapted with permission 
 
2-1b. Location of the Central Pattern Generator within the 
brainstem, specifically the medulla oblongata and its relation 
with the nucleus of the solitary tract (red), the dorsal motor 
nucleus of the vagus (green), the reticular formation (blue) 
and the Chemoreceptor Trigger Zone (CTZ) (From “Bottom 
View of the Human Brain” by Alexluengo 
(image32775557#res1218957). Copyright [2017] by  
Dreamstime.com Purchased and adapted with permission). 
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mucosa. Numerous serotonin receptors are found in the GI tract and in the Central Nervous 
System (CNS) including the CTZ (Gan, 2005).  
  
 
 
 
Figure 2-2:  Innervation of the Gastrointestinal Tract: Efferent pathways to the 
anatomical areas involved in the vomiting process, following visceral distension and 
stimulation of the Central Pattern Generator.  
(From “Brain with spinal cord anatomy” by Magicmine (image 75075628#res1218957); “Human 
stomach anatomy” (image74203719# res1218957); “Human Intestine Anatomy” (image 
74201261#res1218957); “Human Diaphragm Anatomy” ( image 74201220#res1218957) by Nerthuz 
Copyright [2017] by Dreamstime.com Purchased and adapted with permission). 
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The third pathway responds to the activation of one or more descending projections from 
the cerebral cortex and thalamus and can trigger vomiting through stimulation via histamine (H) 
and acethylcholine (Ach) receptors. Different factors are believed to trigger nausea and vomiting 
involving the cerebral cortex, including emotions, anxiety, raised intracranial pressure and 
meningeal irritation  (Neoh, Adkinson, Montgomery, & Hurlow, 2014). This activation can be 
seen after the stimulation of the temporal lobe (amygdala) and the insular cortex during an 
epileptic seizure, which can be associated with ictal vomiting (Horn et al., 2014).  
 
The fourth pathway activated by movement of the inner ear stimulates the vestibular and 
labyrinthine regions, originating a chemical signal. This signal, along with the signals from the 
limbic area and cerebral cortex, transmits central stimuli to the vomiting center (Fig. 2-3 and 2-4)  
(Sweis, Yegiyants, & Cohen, 2013).  
 
Lesions affecting the cerebellum also are a significant cause of nausea and vomiting, as 
isolated or associated symptoms. This is frequently seen in patients suffering from cerebellar 
strokes who may experience vomiting, usually insidious and difficult to treat. It is thought that 
the main cause for the vomiting symptom is the closeness of the cerebellum to the fourth 
ventricle as a triggering point stimulating the AP and CTZ  (Horn et al., 2014; Su & Young, 
2011) 
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Figure 2-3: Brain pathways involved in the vomiting process - Sagittal plane showing 
the pathways between the vestibular system and the areas in the thalamus, the limbic 
system, the cerebellum and the brainstem, the latest including the vestibular nuclei 
(red), the central pattern generator (orange) and the vestibulospinal tract.  
(From “Dissected Brain Lateral View” by Alexluengo (image32775542#res1218957);   “Ear anatomy” 
by Andegraund548 (image 49749512#res1218957)  Copyright [2017] by Dreamstime.com Purchased 
and adapted with permission). 
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Figure 2-4:  Area Postrema  
This figure shows the Circumventricular organs including the area postrema, characterized 
by its rich vasculature and lack of normal blood-brain barrier. It also shows the location of 
the Chemoreceptor Trigger Zone (CTZ) (orange) within the area postrema and its relation 
to the Central Pattern Generator  
(From “Dissected Brain Lateral View” by Alexluengo (image32775542#res1218957) Copyright [2017] by 
Dreamstime.com Purchased and adapted with permission). 
 
All the above-mentioned pathways stimulate the vomiting center and are in close relation 
to neuronal pathways within the cerebral cortex and the autonomic nervous system, specifically 
in areas associated with balance, salivation, respiration and vasomotor activity, including the 
perception of nausea. The association among these specific areas also explains the physiological 
responses of salivation, sweating, pallor and tachypnea, which are often described as 
accompanying the vomiting process (Sweis et al., 2013).   
 
On a similar line, associated to the process of vomiting is the subjective feeling of nausea. 
This common symptom is defined as an "unpleasant painless subjective feeling that one will 
imminently vomit" (Hasier and Chey , 2003; 2016 Singh). Furthermore, patients have reported 
nausea, as more disabling, worse feeling that lasts longer than the actual act of vomiting (Stern et 
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al, 2011; 2016 Singh). Similar to the process of vomiting, the stimuli for nausea is also originated 
from the vestibular area, the visceral pathway and the CTZ as explained earlier. Studies have 
suggested that apart from the pathways involved in the process of vomiting, the process of nausea 
also correlates with specific areas of the cerebral cortex that are involved in higher cognitive 
function and emotion including the medial prefrontal cortex (Miller, 1999; Napadow et al, 2013; 
Singh, 2016). This may explain why nausea may be present in the absence of vomiting, through 
the persistent stimulation of these areas in the cerebral cortex (Napadow et al, 2013;  Horm, 
2008; Singh, 2016).    
 
Having described the different pathways associated with the process of nausea and 
vomiting, we turn now to the final result, the act of vomiting.     
 
 
2.1.2.1 The act of vomiting 
 
The act of vomiting comprises three phases known as the pre-ejection phase, the ejection 
phase and the post-ejection phase. The pre-ejection phase includes prodromal signs and 
symptoms perceived as nausea, pallor, salivation and visceral function changes, such as 
tachycardia. This phase can last from minutes to days, depending on the type of stimuli.  
 
The ejection phase comprises retching and the final expulsion of the gastric contents. 
Retching is the synchronous contraction of the diaphragm, external intercostal muscles and 
abdominal muscles with a closed glottis, leading to a change in the intra-thoracic and intra-
abdominal pressure, decreasing and increasing, respectively. Vomiting completes this phase. It is 
the expulsion of gastric contents after relaxation of the upper esophageal sphincter and intense 
contraction of the abdominal muscles, leading to an increase of intra-thoracic and intra-
abdominal pressure to about 100 mmHg (Pleuvry, 2012). 
 
The post-ejection phase is the final phase in this process and follows a characteristic 
posture adopted to minimize the strain of muscles and structures not involved in the process and 
to optimize compression that other muscles may apply over the stomach.  
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 Patients may experience prodromal signs and symptoms pertaining to the pre-ejection 
phase that can potentially progress to the actual act of vomiting. The patient’s ability to 
communicate and express this uncomfortable feeling may be encouraged if therapy for the 
prevention or management of symptoms is received in a timely fashion. However, children, 
especially younger patients, may have major difficulty communicating their discomfort to care 
givers, making the recognition of high risk patients an important component for the adequate 
prevention and treatment of this condition.  
 
 
2.2   Postoperative nausea and vomiting     
 
Many conditions have been associated with the occurrence of nausea and vomiting. 
Examples of these conditions include side effects from medications, ingestion of toxins, motion, 
traumatic events and perioperative factors, the latter related to PONV (Becker, 2010). 
 
PONV is recognized as one of the most common causes of morbidity following surgery 
(Apfel, Philip et al., 2012; Gan et al., 2014).  Its impact on patient recovery emphasizes the 
importance of recognizing associated factors, allowing clinicians to identify patients at higher 
risk of this postoperative complication. 
 
 
2.2.1.  Risk factors associated with postoperative nausea and vomiting  
 
Risk factors associated with postoperative nausea and vomiting (PONV) are generally 
divided into three main groups: 1. Patient-related factors; 2. factors related to the nature and 
extent of the surgical procedure; and 3. factors associated with medications administered during 
the perioperative period including analgesics and anaesthetic agents (Apfel et al., 2012; Becker, 
2010). 
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    Total Score            PONV risk 
0  10%  
1  20% 
2  40% 
3  60% 
4  80% 
2.2.1.1.  Patient-related risk factors associated with PONV  
 
Patient-related risk factors have found to be consistent in numerous studies that evaluated 
the occurrence of postoperative nausea and vomiting. In adults, the factors identified to be 
independent predictors include female sex, younger age, non-smoking status and prior history of 
PONV or motion sickness (Apfel et al., 2012; Apfel et al., 2012; Horn et al., 2014). One meta-
analysis of 22 studies and a total of 95154 patients identified similar main risk factors for PONV 
and showed an overall incidence of PONV of 35% (18-45%) (Apfel et al., 2012). Although the 
reason why being a female increases the risk of PONV more than twice that of males (OR=2.6) is 
unknown, this risk in female patients, especially in post-pubertal females, persists throughout life 
and is identified as the strongest independent patient-related predictor factor (Apfel et al., 2012; 
Gan et al., 2014). Other patient-related factors such as history of migraine, high body mass index 
and physical status classification are less likely to have a consistent correlation with increased risk 
of PONV (Becker, 2010; Gan et al., 2014; Horn et al., 2014). The main risk factors and their 
respective quantified risk are listed in Table 2-1, adapted from the “Simplified Apfel Risk Score” 
(Apfel et al., 2012; Gan et al., 2014).  
 
Table 2-1: Risk of PONV in adults. 
 
Risk Factor Points 
Female Sex 1 
Non-smoker 1 
History of PONV 1 
Postoperative opioids 1 
Total Score 0 to 4  
 
Simplified Apfel risk score for PONV in adults. The PONV risk increases in relation to the number 
of factors present. Apfel et al. British Journal of Anesthesia 2012; Gan et al. Anesthesia & 
Analgesia 2014.  
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In children, associated patient-related risk factors for PONV are difficult to assess and 
differ significantly from those identified in adults. Previous studies have identified the major 
patient-related factors for PONV in children and resulted in the development and validation of a 
specific risk score known as the Postoperative Vomiting in Children (POVOC) score (Eberhart et 
al., 2004(L. Eberhart et al., 2004; Kranke et al., 2007). The main factors strongly associated with 
the occurrence of PONV were childhood and a prior history of PONV (Eberhart et al., 2004 (L. 
Eberhart et al., 2004; Horn et al., 2014). A recent study of 2392 pediatric patients identified and 
quantified the specific independent risk factors for children, modifying the previous POVOC 
score by adding two more factors related to the surgical procedure (Tables 2-2 and 2-3) (Bounard 
et al., 2014). The differences between the adult and pediatric populations are reflected in the 
development of guidelines for the management of PONV specific to each population, which are 
discussed in the following sections.  
 
 
Table 2-2: Risk of PONV in children. 
  
Risk Factor Points 
Age       > 3 years 1 
History of PONV or PONV in 
relatives 
1 
Strabismus surgery 1 
Surgery duration > 30 min 1 
Total Score 0 to 4  
 
 
Simplified Risk Score for PONV in children. The PONV risk increases in relation to the number 
of factors present.  
Eberhart et al. Anesthesia & Analgesia 2004.  
 
 
 
 
Total Score                PONV risk 
0  10%  
1  10% 
2  30% 
3  50% 
4  70% 
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Table 2-3: Risk of PONV in children based on the POVOC score. 
 
Risk Factor Points 
Age       < 3 years 
              >3 and < 6 or > 13 years 
              > 6 and < 13 y 
0 
1 
2 
History of PONV or PONV in 
relatives 
1 
Surgery at risk 
     Tonsillectomy 
     Tympanoplasty      
     Strabismus surgery 
     Other 
  
 
1 
 
0 
Surgery duration > 45 min 1 
Multiple doses of Opioids  1 
Total Score 0 to 6  
 
Additional risk factors included in the Postoperative Vomiting in Children (POVOC) risk score for 
children. Kranke et al. Anesthesia & Analgesia 2007.  
 
 
2.2.1.2.  Surgery-related risk factors associated with PONV 
 
The majority of the studies looking at PONV in adults have been conducted in patients 
undergoing ambulatory surgery and demonstrated that the nature and extent of some surgical 
procedures are associated risk factors for PONV.  The results of the studies identified procedures 
with the highest incidence of PONV and their possible underlying mechanisms that trigger the 
vomiting process (Apfel et al., 2012; Gan et al., 2014; Horn et al., 2014). The surgical procedures 
and their associated mechanisms include the following: the stimulation of the vestibular system 
caused during tympanoplasty; the presence of blood in the GI tract swallowed during ENT and 
oral surgery; significant anxiety in patients undergoing breast surgery; peritoneal irritation caused 
in Minimally Invasive Surgery (MIS) also known as laparoscopic surgery; and gastrointestinal 
and vagal stimulation produced by abdominal and gynaecological procedures, especially 
        
Total Score               PONV risk 
0 to 1  Low  
2 to 3  Medium 
4 to 6  High 
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hysterectomy (Becker, 2010). Despite these possible explanations, none of the procedures have 
been demonstrated to be independent predictor factors for PONV (Apfel et al., 2012).   
 
Surgery-related risk factors in pediatric patients include the type and duration of the 
surgical procedure (more than 30 minutes) as highlighted in the modified POVOC score (Table 
3) (Bounard et al., 2014).  Most of the previous studies of PONV in the pediatric population were 
conducted in patients undergoing strabismus correction surgery, leading to the identification of 
only this procedure as the main surgery-related risk factor for PONV (Apfel et al., 2012; L. 
Eberhart et al., 2004). The new revised POVOC score includes tonsillectomy and tympanoplasty, 
along with strabismus corrective surgery, as the main surgical procedures identified as 
independent risk factors associated with the occurrence of PONV (Bounard et al., 2014).     
 
The duration of the surgical procedure is the other significant factor in this group. This is 
directly related to the length of exposure to anesthetic agents, which are discussed with the next 
group of risk factors (Becker, 2010).    
  
In addition, it is important to review the impact of sedation or general anesthesia in 
patients undergoing non-surgical procedures. The National Clinical Guide Centre (NCGC) and 
the National Institute for Health and Clinical Excellence (NICE) guidelines for the sedation in 
children and young people, delineate the standard procedure for procedural and treatment 
sedation in this population (National Clinical Guideline Centre, 2010). These guidelines define 
sedation as “ a state of depressed consciousness. There are depths or levels of sedation that 
range from minor to major depression of consciousness”, without causing significant depression 
of airway reflexes or breathing, and General anesthesia as “drug-induced loss of consciousness 
during which patients are not rousable, even by painful stimulation. Patients require assistance 
in maintaining a patent airway” (National Clinical Guideline Centre, 2010). To achieve this, the 
NICE guidelines present various important aspects for the success of procedural sedation and 
general anesthetic in children undergoing diagnostic or therapeutic procedures. These aspects 
include adequate pediatric patient preparation, the involvement of parents and an appropriate 
child-oriented environment (National Clinical Guideline Centre, 2010).  
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The most common non-surgical procedures requiring sedation or general anesthetic, 
accounting for 90% are classified as painless imaging procedures such as MRI or CT scan; 
painful procedures such as changes of wound dressings, minor trauma ER procedures and 
orthopedic manipulation; dental procedures and endoscopy. In a quality assurance, prospective 
study that included 922 children ages birth to 18 year of age, who underwent sedation (n=782) or 
general anesthesia (n=140) for CT scan (n=392) or MRI  (n=530) procedures (Malviya 2000), the 
time of the procedure was related to adequacy of the sedation ranging from 37 to 52 minutes. 
These impacted their exposure to the sedative or anesthetic agent and possible side effects after 
the procedure. Overall only 12 patients (1.3%) presented with post procedural nausea and 
vomiting, among other medication related adverse effects which in total accounted for 3.6% of 
the population. Although, the direct association of nausea and vomiting was not reported, in 
general it was reported that the use of a single or multiple agents did not show any difference in  
overall adverse effects (Malviya 2000).  
 
  2.2.1.3.  Perioperative medications associated with PONV 
 
The last group of factors that influence PONV, known as emetogenic agents, consist of 
analgesics and anaesthetic medications used in the perioperative period. Among analgesics, 
opioids are an important part of the perioperative management because of the pain control they 
provide, which contributes to the anesthetic process. Despite their benefit, opioids have been 
identified as one of the primary risk factors associated with PONV (Apfel et al., 2012; Horn et 
al., 2014). Theories behind the proemetic effect of opioid medications rely on their action on μ 
receptors located within and outside the blood-brain barrier, the area postrema, and possibly the 
nucleus of the solitary tract (Horn et al., 2014). It is believed that the degree of risk of PONV is 
most likely due to the total opioid dose administered, rather than the agent and time it is given 
during the perioperative period (Becker, 2010). Furthermore, some studies suggest that 
intraoperative opioid use is less likely to be a continuous stimulus compared to opioid use in the 
postoperative period because the emetogenic stimuli is relatively stronger (Apfel et al., 2012; 
Horn et al., 2014). In addition, the fact that PONV during the postoperative period is more 
frequently seen with ambulation suggests that a vestibular component may be implicated (Becker, 
2010; Longnecker et al., 2011). 
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The other emetogenic agents are the anaesthetic medications used during the anaesthetic 
process. The anesthetic procedure depends on the following: The type of anaesthesia chosen 
based on the nature and length of the surgical procedure; the level of sedation needed; the setting 
where the surgical procedure will take place (hospital or outpatient setting); the patient’s 
underlying physical and physiological status prior to surgery, also known as the American 
Society of Anesthesiologists (ASA) physical status classification (ASA Classification, Table 2-
4); and the qualifications and experience of the anaesthetic provider  (American Society of 
Anesthesiologists., 2014; R. D. Miller, Eriksson, Fleisher, Wiener-Kronish, & Young, 2010). The 
ASA status classification does not include the type of anesthesia or the nature of the surgical 
procedure; instead, it focuses on the quantification of the patient’s risk associated with the 
surgery and the anesthetic. The presence of underlying medical conditions and aging are the key 
determinant factors for the type of anesthetic to be administered (Longnecker et al., 2011). The 
types of anaesthesia are broadly classified as general, regional, monitored anaesthesia care and 
local anaesthesia (Longnecker et al., 2011; R. D. Miller et al., 2010). Among anaesthetic types, 
general anaesthesia is recognized as a significant risk factor for the occurrence of PONV 
compared to regional anaesthesia  (Apfel, Stoecklein, & Lipfert, 2005).  
 
Table 2-4: ASA Physical Status Classification System.   
Physical 
Status 
Description 
ASA 1 A normal healthy patient 
ASA 2 A patient with mild systemic disease 
ASA 3 A patient with severe systemic disease 
ASA 4 A patient with severe systemic disease that is a constant threat to life 
ASA 5 A moribund patient who is not expected to survive without the operation 
ASA 6 A declared brain-dead patient whose organs are being removed for donor purposes 
E A patient requiring an emergency operation  
 
American Society of Anesthesiologists (ASA) Adapted from Miller, R.D. et.al, Miller’s 
Anesthesia, Churchill      Livingstone Elsevier, 2010 
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To better understand the role of general anesthesia as a risk factor for PONV, it is 
important to explain the main components of this process. General anesthesia has three main 
phases known as induction, maintenance and emergence or recovery. These phases should be 
achieved during the anesthetic process in order to provide the ideal operative conditions and 
accomplish patient safety and satisfaction (Longnecker et al., 2011). The anesthetic process uses 
two main types of anesthetic medications: inhalational anesthetic agents, known as gaseous 
(nitrous oxide) and volatile (e.g., sevoflurane and isoflurane) anesthetics; and intravenous 
anesthetics. Among their potential mechanisms of action, specific pathways have been identified 
to decrease neuronal excitability by enhancing their inhibitory activity via inhibition (intravenous 
anesthetic – propofol) and modulation (volatile anesthetics) of gamma-aminobutyric acid type A 
(GABAA) receptor, or the inhibition of a potent excitatory glutamate receptor, the N-methyl-D-
aspartate (NMDA) (Nitrous oxide).   
 
Inhalational anesthetics are also considered the strongest anesthesia-related risk factor for 
the occurrence of postoperative nausea and vomiting (PONV), especially volatile anesthetics, 
more so than nitrous oxide, because their high potential to produce PONV increases with the 
length of exposure (Apfel et al., 2002; Becker, 2010; Gan et al., 2014; Horn et al., 2014).  
 
In a literature review, the strong dose-response association between the exposure to 
volatile anesthetics and the incidence of PONV was most commonly seen during the early 
postoperative period (0 to 2 hours postoperatively) (Apfel et al., 2002). This association was 
supported by a significant 19% reduction in PONV incidence when the use of volatile anesthetics 
was avoided during the anesthetic process (Apfel et al., 2005). In addition, in a large controlled 
multicenter study of 17,201 participants, the incidence of PONV was found to be similar among 
different volatile anesthetics (Apfel et al., 2005; Forrest et al., 1990). The same results were 
found in a meta-analysis that compared the modern volatile anesthetics - sevofluorane and 
desflurane – and showed that the emetogenic effect of the volatile anesthetic was about the same 
for both medications  (Apfel et al., 2005; Macario, Dexter, & Lubarsky, 2005).  
 
Compared to volatile anesthetics, nitrous oxide (N2O) has a weaker association with the 
occurrence of PONV. Studies have shown that the omission of nitrous oxide decreases the risk of 
PONV by a statistical but not clinical significance  (Apfel et al., 2005; Divatia, Vaidya, Badwe, 
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& Hawaldar, 1996). One meta-analysis of 30 studies and 4598 patients demonstrated that when 
nitrous oxide was avoided, an overall reduction of 20% in the risk of PONV was seen. This 
reduction was found to be small when comparing the absolute difference in the incidence of 
PONV between N2O and non-N2O groups  (Fernandez-Guisasola, Gomez-Arnau, Cabrera, & 
Garcia del Valle, 2010). Another meta-analysis of 29 studies and 10317 patients showed that the 
increased incidence of PONV was seen in direct relation to the time of exposure, and was 
especially pronounced after an hour of exposure  (Peyton & Yx Wu, 2014).   
 
In a Cochrane Interventional Review of 16 studies and 900 children, the increased risk of 
PONV associated with inhalational anesthesia in children was found to be consistent with 
previous studies, showing a PONV incidence difference between sevoflurane and propofol of 
32.6% and 16.1%, respectively, when used during the anesthetic process  (Ortiz, Atallah, Matos, 
& da Silva, 2014). These findings confirm the recognition of volatile anesthetics as the strongest 
anesthesia-related predictor factor associated with PONV, followed by the use of nitrous oxide 
and the duration of anesthesia (Gan et al., 2014; Ortiz et al., 2014). Despite the emetogenic 
effects, inhalational anesthetics continue to be used, especially in children, for the induction of 
general anesthesia when intravenous access is not available at the time of the procedure 
(Longnecker et al., 2011).  
 
In contrast to inhalational anesthetics, propofol has been associated with known 
antiemetic properties (Apfel et al., 2005; Becker, 2010; Gan et al., 2014). Propofol is a sedative-
hypnotic commonly used for intravenous induction and maintenance of general anesthesia and 
monitored conscious sedation (Longnecker et al., 2011). Numerous studies done in adults, have 
demonstrated a significant reduction of PONV when propofol is used as the maintenance 
anesthetic. In one of the studies, a Randomized Controlled Trial of 2010 patients, the incidence of 
PONV was reduced significantly when propofol was used as a continuous infusion or Total 
Intravenous Anesthesia (TIVA) compared to inhalational anesthesia. This study showed a 
reduction of the absolute risk of PONV by 15% among inpatients and by 18% among outpatients  
(Visser, Hassink, Bonsel, Moen, & Kalkman, 2001). Another Randomized Controlled Trial with 
5199 patients showed a similar PONV risk reduction of 19% in the propofol group (Apfel et al., 
2004). Likewise, a study of 1180 patients showed a significant difference, especially in the early 
postoperative period (0-2h), between the group that received inhalational anesthetics compared to 
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the group that received propofol, the latter associated with a significantly lower incidence of 
PONV (Apfel et al., 2002). These studies confirm the benefit of propofol showed by the 
significant reduction of PONV and its role as a potential protective factor.  
 
Despite its positive effect on PONV, prolonged Propofol infusions may cause serious 
complications including Propofol Infusion Syndrome which has been described in adult patients, 
specifically in patients at increased risk. This would include but not be limited to patients with 
previous prolonged use of Propofol, with underlying metabolic disorders, critically ill patients, 
and those with carbohydrate depletion conditions. Additionally, Propofol Infusion Syndrome has 
been also described in children with Friederich’a ataxia and metabolic diseases, and may 
influence anesthesiologists to avoid this medication as a maintenance anesthetic agent 
(Mirrakhimov et al. 2015; Wolf, et al. 2001; Wolf A.R., Potter, F. 2004).     
 
Different authors have emphasized the potential effect of some of the discussed 
medications used in the perioperative period on the gastrointestinal function, which may be 
disrupted after their use  (Chassard et al., 2002; Holtmann & Talley, 2014; Wallden, Thorn, 
Lovqvist, Wattwil, & Wattwil, 2006). Numerous studies have demonstrated that opioid 
medications have a significant inhibitory effect on GI motility. Opioid medications are mediated 
via opioid receptors centrally and peripherally. Yuan et al. showed that even at small doses, 
morphine has a significant inhibitory effect on gastric emptying that poses an increased risk for 
PONV and potential aspiration  (Wallden et al., 2006; Yuan, Foss, O'Connor, Roizen, & Moss, 
1998). The inhibitory effect on gastric emptying has also been demonstrated in general 
anesthetics. A study with 50 participants that compared two anesthetic techniques, propofol-
remifentanil and opioid-free sevoflurane, failed to show a significant difference on gastric 
emptying between the two groups, but when compared with gastric emptying in a normal state 
(no surgery, no anesthesia), a significant delay in gastric emptying pattern was seen with the use 
of both anesthetics. As shown in the study, the effect of inhaled anesthetic agents on delayed 
gastric emptying may cease after the agent is discontinued (Wallden et al., 2006). Although some 
evidence suggests that high doses of propofol may inhibit GI motility, a study performed on 10 
healthy volunteers showed that propofol used at subhypnotic doses (light sedation) was not 
associated with gastric emptying delay (Chassard et al., 2002). 
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Overall, the evidence presented in this section supports the importance of recognizing the 
major risk factors for the occurrence of PONV included in the simplified risk score for adults and 
children. This recognition represents the first step in the prevention and management of this 
condition.  
 
 
2.3 Prevention and management of PONV   
 
 In past decades, most research on PONV has emphasized the need to reduce the incidence 
of PONV by identifying patients at high risk for this condition and by developing strategies 
focused on the prevention and management of PONV.  
 
 
2.3.1 Antiemetic medications 
 
 It has become commonplace to differentiate antiemetic medications according to their 
mechanism of action and their efficacy on the antagonist effect at the specific receptor site within 
the vomiting center and associated areas. Based on their site of action, antiemetics can be 
classified as Serotonin (5-HT3) receptor antagonists, substance P - neurokinin (NK1) receptor 
antagonists, dopamine (D2) receptor antagonists, corticosteroids, butyrophenones, histamine 
type1 (H1) receptor antagonists and muscarinic cholinoceptor antagonists (anticholonergics) 
(Table 2-5).  
 
2.3.1.1. Serotonin type 3 (5-HT3) receptor antagonists 
 
 The main agents in this category are ondansetron, dolasetron, granisetron, tropisetron and 
palonosetron. Despite their similar mechanisms of action, these medications differ in their 
chemical configuration and pharmacological properties, including their affinity for the 5-HT3 
receptor, the duration of effect, the dose response and the P450 (CYP) system component 
involved in their metabolism (Gan, 2005).   
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Serotonin receptor (5-HT3) antagonist agents were initially developed to effectively 
control radiation- and chemotherapy-induced nausea and vomiting because this type of therapy 
triggers the release of serotonin from the gastrointestinal wall, stimulating the vomiting center as 
well (Becker, 2010). In the mid 1980s, the effects of metoclopramide were attributed partially to 
serotonin antagonism, which prompted the development of selective serotonin receptor 
antagonists, thus improving the management of nausea and vomiting (Gan, 2005). 
 
The 5-HT3 receptors, identified as sodium channel type receptors, are localized in the 
Central Nervous System (CNS) in the Area Postrema (AP) and throughout the peripheral tissue, 
especially in the bowel (via vagal afferents) and those areas involved in the vomiting process. As 
mentioned, the afferent signals travel along the vagal nerve, reaching the nucleus of the solitary 
tract and the chemoreceptor trigger zone (CTZ), thus stimulating the Central Pattern Generator in 
the brainstem (Becker, 2010; Gan, 2005). All these areas have abundant 5-HT3 receptors, 
suggesting that the inhibition of these receptors at multiple levels of the vomiting process may 
denote a key element for the efficacy of serotonin receptor antagonists (Gan, 2005). 
 
The pharmacokinetic properties of serotonin 5-HT3 receptor antagonists are shown in 
Table 2-6. Of all the agents, ondansetron has the shortest half-life (3.4 hours), which can be 
prolonged in elderly patients (Gan, 2005; Longnecker et al., 2011) and may be relevant when 
comparing different medications and the incidence of PONV, as shown in a randomized 
controlled trial of 75 patients  (Sun, Klein, & White, 1997). This study showed that the incidence 
of PONV in the early postoperative period was similar when ondansetron was administered at 
different times during the perioperative period (induction and emergence), but that there was a 
significantly lower requirement of rescue antiemetics in the recovery area when ondansetron was 
administered at the end of the procedure. This observation can possibly be explained by the 
relatively short half-life of ondansetron, which could contribute to the apparent ineffectiveness of 
this medication when administered at the beginning of the procedure (Sun et al., 1997).  
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Table 2-5: Classification of antiemetics. 
Antiemetic type Site of action Location Antiemetics 
Serotonin 
receptor 
antagonist 
Serotonin 5-HT3 
Sodium channel type 
CNS     - Area 
Postrema 
Peripheral tissue 
      - Bowel wall 
Ondansetron 
Granisetron 
Palonosetron 
Substance P-
neurokinin 
receptor 
antagonists 
Substance P receptor - Neurokinin NK1 CNS     - Area Postrema  
      - NST 
Peripheral tissue 
      - Bowel 
Aprepitant 
Dopamine 
receptor 
antagonists 
Dopamine receptor  
*Metoclopramide selective for D2-dopamine 
receptor  
- Also have action on H1 and Ach receptors.  
CNS     - Area Postrema 
      - CTZ 
Promethazine 
Prochlorperazine 
Chlorpromazine 
Metoclopramide 
Corticosteroids 1. Via Prostaglandin antagonism 
2. Endorphine release 
3. Reduction of 5-hydroxytriptophan 
4. Prevents Serotonin secretion at GI tract 
CNS     - Neural tissue 
Peripheral tissue  
      - GI Tract 
Dexamethasone 
Prednisone 
Butyrophenones Dopamine receptor – D2 (antagonist) CNS      - Area 
Postrema 
       - CTZ 
Haloperidol 
Droperidol 
Histamine 
receptor 
antagonists 
Histamine type 1 (H1) 
Muscarinic receptors 
CNS      - Area 
Postrema 
Peripheral tissue 
     - GI Tract 
     - Labyrintine system 
Dimenhydrinate 
Promethazine 
Cyclizine 
Muscarinic 
cholinoceptor 
antagonists 
(Anticholinergics) 
Post-ganglionic muscarinic receptors Nervous System 
      -ANS 
      - Medulla 
Oblongata 
Peripheral tissue 
      - GI Tract 
Scopolamine 
Atropine 
 
Adapted from Gan et al. Anesthesia & Analgesia 2014 and Kovac, A.L. Drugs 2013.  
 
 
A Cochrane review analysis of 737 studies and 103,237 patients showed no evidence that 
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during induction, intraoperatively or postoperatively), although treatment of nausea and vomiting 
was seen more often in cases when ondansetron was given intraoperatively  (Carlisle & 
Stevenson, 2006).  
 
Of the first generation 5-HT3 receptor antagonist medications, ondansetron is the most 
commonly used antiemetic and is considered to be the “gold standard” when compared with other 
antiemetics  (Gan et al., 2014; Horn et al., 2014; Skolnik & Gan, 2014). Since 1991, different 
studies assessing the antiemetic efficacy of ondansetron have shown that this medication is as 
effective as other serotonin receptor antagonists and other antiemetics, including dexamethasone 
(Apfel et al., 2004; Gan, 2005; Subramaniam et al., 2001). A randomized controlled trial of the 
data of 4123 patients found that ondansetron, dexamethasone and droperidol each reduced the 
risk of postoperative nausea and vomiting by about 26 percent, indicating that the different 
antiemetic medications are similarly effective for the prevention of PONV (Apfel et al., 2004).  
 
Compared to ondansetron and other medications in this category, palonosetron, a second 
generation 5HT3 antagonist, has a prolonged plasma half-life of 40 hours, which may explain its 
complete response (no vomiting episodes or rescue antiemetics) during the first 24 hours after the 
administration of a single dose before induction of anesthesia, as shown in a study of 574 patients  
(Candiotti, Kovac, Melson, Clerici, & Gan, 2008). A RCT of 98 participants that evaluated the 
efficacy of a single dose of palonosetron compared to ondansetron for the prevention of PONV in 
the first 24 hours following surgery failed to show any significant difference in number of PONV 
episodes, suggesting that both medications had similar efficacy despite their different half-lives  
(Laha, Hazra, & Mallick, 2013; Skolnik & Gan, 2014). 
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   Table 2-6: Pharmacokinetic properties of antiemetic medications.   
 
Adapted from The Compendium of Pharmaceuticals and Specialties (CPS), Canadian Pharmacists Association, 2014
Antiemetic type Medication Absorption PPB Half life Metabolism Excretion 
Serotonin 5-HT3 
Receptor antagonist 
Ondansetron 
Granisetron 
 
Palonosetron 
IV complete; oral 60 % 73 % 3 - 4 hr Urinary metabolites Urine and feces 
IV complete; oral 60 % 65 % 4 - 6 hr Hepatic via CYP3A4 and 
CYP1A1 
IV complete; Oral almost 100% 62 % 37 hr Hepatic via CY2D6 and 
CYP3A4 
Substance P- NK1 
receptor antagonist 
Aprepitant Oral availability 65% 95% 9 – 13 hr Hepatic CYP3A4 Metabolites / Feces 
Dopamine receptor 
antagonists 
Promethazine 
Prochlorperazine 
Metoclopramide 
Complete oral absorption 93 % 9 – 16 hr Hepatic / Oxidation Urine and feces 
IV complete; Oral 5.7 % 90 % 7 – 9 hr Hepatic Bile and feces 
IV complete - Oral 30 – 70 % 40 % 3 – 5 hr Metabolized to sulphate and 
glucuronide conjugates 
Urine  
 
Corticosteroids Dexamethasone 
 
Prednisone 
IV complete; Oral Almost 
complete 
77 % 1.8 – 3.5 hr Hepatic CYP3A4 Metabolism and 
renal excretion 
Converted to prednisolone  > 90% 2 – 4 hr Hepatic CYP3A4 Hepatic and renal 
Butyrophenones Haloperidol 
 
Droperidol 
Oral 
IM release from fatty tissue  
92 % Oral 20 hr 
IM 3 weeks 
Hepatic CYP3A4 Urine and feces 
IM complete absorption 85 – 90 % Rapid = 1 – 2 min 
Slow = 14–20 min 
Metabolized Mostly renal 
Bile and feces 
Histamine receptor 
antagonists 
Dimenhydrinate 
 
Promethazine 
IV complete; oral almost 
complete 
PPB 98 %  3.5 hr  Hepatic (cytochrome P450) Urine 
Complete oral absorption 93 % 9 – 16 hr Hepatic / Oxidation Urine and feces 
Muscarinic 
cholinoceptor 
antagonists 
(Anticholinergics) 
Scopolamine 
 
 
IV or IM rapid absorption 
Patch 72 hours (5 µ/h) 
Antiemetic onset at 12 hr 
14 – 22 % IV/IM 1 hr 
SC 3.5 hr 
Hepatic  Urine 
Atropine IM rapid absorption 18 % Initial phase 2 – 3 hr  
Terminal phase 12.5 hr 
Hepatic Urine 
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 In children, the use of ondansetron as a prophylactic agent for PONV has been studied as 
well. In a meta-analysis of 13 randomized controlled trials and 2,006 pediatric patients, seven of 
the studies found the incidence of PONV to be lower in the ondansetron group (37.2%) compared 
to placebo (65.6%). Only one of the studies analyzed compared ondansetron with 
dexamethasone, finding an overall PONV incidence that was not significantly different between 
the groups (Shen et al., 2014). 
 
A large volume of published studies compared the efficacy of ondansetron when 
administered at different doses, based on the recommended prophylactic dose of ondansetron as 4 
mg intravenously (IV) or 8 mg orally (Gan et al., 2014). A systematic review, including fifty-
three studies and 12,889 patients who received either a placebo or any of the different 
ondansetron regimens for the prevention of PONV, found that at 4 mg, the Number Needed to 
Treat (NNT) for the prevention of vomiting and nausea was 6 and 7, respectively  (Tramer, 
Reynolds, Moore, & McQuay, 1997). The previously mentioned Cochrane review showed that 
the risk of PONV was increased by 1.43 when onsansetron doses were halved, but the person’s 
age, gender or type of surgery did not impact the effect of the medication  (Carlisle & Stevenson, 
2006). In children, the dose used in the majority of the studies ranged between 0.1 and 0.2 mg/kg, 
(Shen et al., 2014), which correlates poorly with the current recommendations of 0.05-0.1 mg/kg 
(up to 4 mg) for the prevention and management of PONV in children (Gan et al., 2014). 
 
 
2.3.1.1.1. Side effects of serotonin (5-HT3) receptor antagonists 
 
 General side effects and their incidence have been identified with the use of 5-HT3 
receptor antagonists. The most commonly reported side effects in adults and children are 
headache (4-22%) and constipation (1-19%)  (Canadian Pharmacists Association, 2014; Carlisle 
& Stevenson, 2006). 
 
Other reported adverse effects include diarrhea (8-16%), malaise or fatigue (9-13%), 
drowsiness (8%), anxiety (6%), fever (7-8 %), urinary retention (5%), itchiness (1-5%) and pain 
at the injection site (4%), flushing (<1%), dizziness (0.01%), movement disorders (0.1 – 0.3%) 
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and electrocardiographic changes, including QTc prolongation (<1%), which could lead to the 
development of Torsades de Pointes (Canadian Pharmacists Association, 2014). 
 
There are special warnings related to potential ECG changes. As suggested in the e-
Compendium of Pharmaceuticals and Specialties (e-CPS), “All 5-HT3 receptor antagonists cause 
a dose-dependent prolongation of the QTc interval” (Canadian Pharmacists Association, 2014). 5-
HT3 antagonists’ mechanism of action consists of blocking sodium channel conductance, 
requiring special precautions in patients with significant electrolyte imbalance, pre-existing 
cardiac conduction abnormalities or arrhythmias, as well as in other patients receiving 
medications that could potentially prolong the QTc interval (tricyclic antidepressants, venlafaxine 
citalopram, clarithromycin and methadone) (Canadian Pharmacists Association, 2014; Gan, 
2005). 
 
A systematic review failed to find any reports of cardiac arrhythmias in adults associated 
with only one dose of ondansetron. In contrast, this review found the occurrence of cardiac 
arrhythmias in 49 reports associated with more than a single dose of ondansetron, mainly 
administered intravenously. Correlation was seen in patients with risk factors for developing 
cardiac arrhythmias, including electrolyte imbalance, cardiac arrhythmias or interaction with 
medications also associated with QTc prolongation  (Freedman, Uleryk, Rumantir, & Finkelstein, 
2014). Based on the updated Drug Safety Communication published by the Food and Drug 
Administration in 2012, ondansetron was associated with dose dependent prolonged QTc and 
routine screening, and ECG studies were not necessary unless patients with a significant medical 
history and associated risk factors were identified or when an intravenous dose over 16 mg of 
ondansetron was required (Food and Drug Administration, U.S., 2012; Freedman et al., 2014).   
 
 Likewise, adverse effects of 5-HT3 in children have been reported with similar 
occurrences to those described in adults. However, in a systematic review, fewer publications and 
reported cases of prolonged QTc were found for pediatric patients (Freedman et al., 2014). 
Eleven pediatric cases associated with prolonged QTc interval were identified, but, in many 
cases, ondansetron was used concomitantly with other pro-arrhythmic medications. The cases 
failed to show a significant correlation between the administration of ondansetron and the 
occurrence of QTc prolongation (Freedman et al., 2014). Another randomized study of 80 healthy 
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pediatric patients failed to find significant ECG differences when ondansetron and droperidol 
were compared. Both medications had an increased QTc interval that remained within the normal 
limits  (Mehta, Sanatani, & Whyte, 2010). Similar recommendations are to be followed for both 
children and adults, including the identification of patients at higher risk of developing cardiac 
arrhythmias and proper administration of these 5-HT3 antagonists’ medications following the 
recommended preventive and management doses guidelines (Tables  2-7 and 2-7a) (Gan et al., 
2014).  
 
 
2.3.1.2. Substance P - neurokinin (NK1) receptor antagonists 
 
 Substance P – Neurokinin (NK1) receptor antagonists prevent the binding of substance P 
to the neurokinin receptor (NK1R).  Since the discovery of substance P and its receptor in 1931, 
this substance was isolated from the emetic centers of the brain at the NST (Nucleus of the 
Solitary Tract) and the AP (Area Postrema) and from the bowel. However, it was not until the 
1990s that the antagonist medications that would block the receptor effectively and had a 
prolonged half-life (40 hours) were used to manage nausea and vomiting especially delayed 
chemotherapy-induced nausea and vomiting (Aziz, 2012; Gan et al., 2014). 
 
 Aprepitant is the only NK1R antagonist medication approved by the FDA. A RCT 
comparing aprepitant and ondansetron for the prevention of PONV showed similar responses at 
24 hours in the postoperative period. In the longer postoperative period, aprepitant was 
significantly more effective than ondansetron beyond the 24-hour period after surgery for the 
reduction of nausea and vomiting (Diemunsch et al., 2007; Gan et al., 2014). Another multicenter 
RCT that analyzed data from 805 participants showed similar results, demonstrating superior 
efficacy compared to ondansetron in the prevention of vomiting in the first 24- and 48- hour 
period, albeit not for nausea control or antiemetic rescue medication requirements (Gan, Apfel et 
al., 2007).  
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2.3.1.2.1. Side effects of substance P - neurokinin (NK1) receptor  
    antagonists 
 
 The main adverse effect of NK1R antagonists is associated with the increased 
bioavailability of dexamethasone when administered concurrently with these medications, 
increasing the incidence of infection among patients treated with both medications (Aziz, 2012). 
 
 These medications are mostly used for chemotherapy-induced nausea and vomiting, but 
further studies are needed to investigate their benefit in the prevention of PONV and their use in 
the pediatric population. The recommended doses are listed in Tables 2-7 and 2-7a (Gan et al., 
2014). 
 
 
 
2.3.1.3. Dopamine (D2) receptor antagonists and butyrophenones 
 
 The antiemetic effect of dopamine (D2) receptor antagonists and Butyrophenones is 
attributed to a competitive antagonism of dopamine (D2) receptors at the CTZ (Chemoreceptor 
Trigger Zone) / AP (Area Postrema), specifically by the inhibition of adenylate cyclase, altering 
the content of AMPc within the neurons located at the AP and the NST  (Horn et al., 2014; 
Skolnik & Gan, 2014).  
 
Medications that pertain to this category include promethazine, prochlorperazine 
Chlorpromazine and metoclopramide. Haloperidol and droperidol, other dopamine receptor 
antagonist agents also known as butyrophenones, are frequently used as highly potent 
neuroleptics, and their antiemetic properties have also been recognized  (H. S. Smith, Cox, & 
Smith, 2012). 
 
Although an antipsychotic, chlorpromazine was used for years as an effective antiemetic 
in patients requiring antineoplastic medications, and the published experienced using this 
medication as an antiemetic agent is significant. With the introduction of newer antiemetic 
medications, when chlorpromazine was compared for its antiemetic properties it was not as 
effective. In a study comparing other antiemetics with chlorpromazine in children, this 
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medication failed to show significant improvement preventing vomiting as the other medications, 
and was associated with possible preventable extrapyramidal symptoms  (Dupuis et al., 2013; 
Marshall, Kerr, Vowels, O'Gorman-Huges, & White, 1989).    
  
Metoclopramide, a derivative of procainamide, is a commonly used antiemetic that also 
acts as a selective agonist of a specific type of serotonin receptor (5-HT3), which creates 
prokinetic action along the upper gastrointestinal tract by increasing the lower esophageal 
sphincter tone, thereby increasing gastric motility and promoting gastric emptying (Becker, 
2010). A multicentre study of 3140 patients compared different doses of metoclopramide in 
combination with dexamethasone (Wallenborn et al., 2006). The risk of vomiting increased after 
smaller doses of metoclopramide were given  (Carlisle & Stevenson, 2006).  
 
 Previous studies have shown that droperidol is as effective as dexamethasone and 
ondansetron for the prevention of PONV, including a Cochrane review, which also demonstrated 
that the effectiveness of the medication was not influenced by the patient’s age, gender, the type 
of surgery performed, or the time in relation to the procedure for which the medication was 
administered. It was evident that smaller doses of droperidol increased the risk of PONV 
compared to larger doses (Horn et al., 2014). This type of medication is not used as a first line 
antiemetic prophylaxis as will be explained later in the section.  
 
 
       2.3.1.3.1. Side effects of dopamine (D2) receptor antagonists 
 
 The inhibition of D2 receptors’ main adverse effects is mediated by interfering with the 
dopamine transmission within the basal ganglia, resulting in different movement disorders known 
as extrapyramidal syndrome. This syndrome includes akathisia, tardive dyskinesia and 
Parkinsonian symptoms (Becker, 2010). The incidence of extrapyramidal syndrome is dose 
dependent, as shown in a study of 3140 patients who received metoclopramide at different doses 
along with dexamethasone. The antiemetic effects were seen mostly within the early 
postoperative period (0-12 hour). Doses between 10 and 25 mg and a higher dose (50 mg) were 
needed to achieve a prolonged antiemetic (from 12 to 24 hours).  Other adverse effects 
documented in the study included hypotension and tachycardia, with an incidence of either event 
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that increased with the dose (8.8% for 0 mg, 11.2% for 10 mg, 12.9% for 25 mg and 17.9% for 
50 mg) (Food and Drug Administration, U.S., 2001; Wallenborn et al., 2006). 
 
 A safety alert was released in 2001 by the Food and Drug Administration after cases of 
death associated with QTc prolongation and Torsades de Pointes with the use of droperidol were 
reported.  The safety alert included new dosage ranges for droperidol below the previously 
recommended dose and instructions to use this medication as a last resource once patients have 
failed to respond to other first line antiemetic medications (Food and Drug Administration, U.S., 
2001; Gan et al., 2014). Further studies have demonstrated that droperidol had similar safety 
parameters to ondansetron at doses for the prevention of PONV below the previously 
recommended dose (Mehta et al., 2010). Recommended doses for dopamine receptor antagonists 
for prevention and management of PONV are shown in Tables 2-7 and 2-7a.   
 
 
2.3.1.4. Corticosteroids 
 
 In 1993, the antiemetic effect of corticosteroids was described for the first time, followed 
by subsequent studies that confirmed its efficacy. After all these years, the antiemetic mechanism 
of action of corticosteroids for the prevention of PONV is not well understood  (Henzi, Bernhard, 
Tramèr, & Phil, 2000). 
 
Different mechanisms of action have been proposed for the antiemetic effect of glucocorticoids, 
including the following  (Henzi et al., 2000; Holte & Kehlet, 2002). 
 
1. Via prostaglandin antagonism  
2. Endorphine release resulting in mood elevation with a subsequent sense of well being and 
appetite stimulation.  
3. Possible reduction of 5-hydroxytryptophan in neural tissue and decrease in tryptophan, 
which may have proemetic effects.  
4. Prevention of serotonin release from the gastrointestinal tract secondary to its anti-
inflammatory effect. 
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5. Possible potentiation of other antiemetics through the sensitization of pharmacological 
receptors, including the 5-HT3 receptor.  
 
    Multiple studies have been conducted comparing glucocorticoids, mainly a single dose of 
dexamethasone alone or in combination with other antiemetics. Dexamethasone has been shown 
to have an important role for the prevention of PONV in several studies (Holte & Kehlet, 2002). 
For example, a systematic review that analyzed 17 trials and data from 1947 patients found that 
dexamethasone was effective in the prevention of PONV (Henzi et al., 2000). This systematic 
review found seven trials, four trials in adults and three in children, comparing dexamethasone 
with placebo. The results were found to be statistically significant in favour of dexamethasone for 
the prevention of postoperative vomiting. The same review found ten studies comparing 
dexamethasone alone with combination of dexamethasone and another antiemetic. The only 
significant benefit by enhancing the antiemetic effect was seen with the concomitant use of 
dexamethasone with ondansetron. 
 
Multiple studies have been conducted on the pediatric population showing similar 
benefits for the prevention of PONV as those shown in adults. One randomized study of 147 
children undergoing tonsillectomy showed that a single dexamethasone injection at the induction 
of the anesthesia reduced the incidence of PONV  (Hermans, De Pooter, De Groote, De Hert, & 
Van der Linden, 2012)In a meta-analysis of 13 RCTs, including 2006 children, the incidence of 
postoperative vomiting was found to be higher in the placebo group than in the dexamethasone 
group (68.2% vs. 34.3%) (Shen et al., 2014). In this study, the combination of ondansetron and 
dexamethasone was significantly more effective for the reduction of postoperative vomiting than 
each antiemetic administered separately. Similarly, a Cochrane review for the use of steroids in 
children analyzed data from 15 studies and 1273 pediatric patients and found a significant 
difference in the incidence of vomiting between patients who received intravenous 
dexamethasone and those who received placebo (21% vs. 48%), favouring steroids for the 
prevention of postoperative vomiting  (Steward, Grisel, & Meinzen-Derr, 2011)  
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2.3.1.4.1. Side effects of corticosteroids 
 
One of the important concerns for corticosteroid administration in children is the possible 
side effects that a single steroid dose can cause. Some of the feared side effects in children have 
been documented after the high dose long-term use of corticosteroids. Some of these side effects 
are decreased growth, peptic ulceration, psychological effects, including aggressive behaviour 
and attention deficit hyperactivity disorder, and osteonecrosis of the hip or any other joint  (Yee 
& Cox, 2013). This last devastating adverse effect was documented in a study of 1409 children 
who received high doses of prednisone for the treatment of leukemia for a period of over 7 years 
(Mattano, Sather, Trigg, & Nachman, 2000). In this study, the incidence of osteonecrosis was 
9.3% and was higher in patients over 10 years of age  (Mattano, Sather, Trigg, & Nachman, 
2000). Similar results were documented in a recently published retrospective study of 1095 
oncologic children, with a cumulative incidence of 3.6% for the occurrence of osteonecrosis in 
children (Hyakuna et al., 2014). However, single and lower dose corticosteroids have been found 
not to cause such detrimental effects and could prevent osteonecrosis, as demonstrated in a 
review where the higher cumulative steroid dose was shown to correlate with worse effects  
(Winkel, Pieters, Wind, Bessems, & van den Heuvel-Eibrink, 2014). 
 
The incidence of infection in patients receiving a single perioperative dose of 
dexamethasone was similar in both dexamethasone and placebo groups in different studies, as 
shown in a systematic review and meta-analysis of 45 studies and 5795 patients  (Waldron, 
Jones, Gan, Allen, & Habib, 2013). Forty studies (1449 patients) failed to report any significant 
difference in the incidence of wound infection in patients that received dexamethasone or 
placebo. The studies also failed to show any significant difference in delayed healing. Another 
study conducted of septic patients show no difference in patient outcomes and complication rates 
between single dose dexamethasone and control groups  (Yee & Cox, 2013). Similarly, a recent 
study of 431 patients failed to show any significant difference for an increased risk of developing 
wound complications or delayed wound healing between the dexamethasone and placebo groups  
(Bolac, Wallace, Broadwater, Havrilesky, & Habib, 2013). 
 
These findings suggest that a single cortisone dose does not increase the incidence of 
postoperative wound infection. Based on the evidence, the use of dexamethasone effectively 
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prevents postoperative nausea and vomiting and should be given after the induction of anesthesia 
as recommended in the Consensus Guidelines for the Management of PONV (Gan et al., 2014). 
Recommended doses for the prevention and management of PONV are shown in Tables 2-7 and 
2-7a. 
 
 
2.3.1.5. Histamine type 1 (H1) receptor antagonists 
 
 
 Numerous histamine type 1 (H1) receptor antagonists have antiemetic properties but are 
not specific on preventing PONV. Agents in this category include promethazine, cyclizine and 
dimenhydrinate, the latest being the most common antihistamine used for the management of 
PONV (Horn et al., 2014). These medications are known to antagonize histamine type 1 (H1) and 
muscarinic cholinergic receptors (RxFiles, 2012). Their main antiemetic effect is attributed to the 
inhibition of histamine and probably muscarinic receptors localized in the AP (Area Postrema) 
and the vestibular nucleus. Second-generation antihistamines (for example, astemizole) do not 
have effective antiemetic properties, as they cannot cross the blood-brain barrier.  
 
A randomized control trial of 133 patients showed a decreased incidence of PONV when 
dimenhydrinate was used compared to the placebo  (L. Eberhart, Seeling, Bopp, Morin, & 
Georgieff, 1999), which was comparable to a meta-analysis of 18 studies and 3045 patients, 
showing that dimenhydrinate had a better relative benefit than the placebo (64% vs. 54%)  
(Kranke, Morinz, Roewer, & Eberhart, 2002). In a Cochrane review, there was not convincing 
evidence of the superior antiemetic effect of dimenhydrinate when compared to ondansetron, 
although cyclizine, another histamine type 1 receptor antagonist, did show a similar antiemetic 
response when compared to other medications, including ondansetron and dexamethasone  
(Carlisle & Stevenson, 2006).  
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2.3.1.5.1. Side effects of histamine type 1 (H1) receptor antagonists 
 
 Although there is insufficient data on the optimal timing, dose response and safety profile 
of histamine type 1 (H1) receptor antagonists for the management of PONV, common side effects 
are related to their associated anticholinergic properties. The most commonly reported side 
effects include drowsiness, urinary retention, dry mouth and blurred vision (Gan et al., 2014; 
RxFiles, 2012).   
  
 
2.3.1.6. Muscarinic cholinoceptor antagonists (sp. anticholonergics). 
  
 The main mechanism of action of muscarinic cholinoceptor antagonists is secondary to 
the competitive inhibition at the post-ganglionic muscarinic receptors in the autonomic nervous 
system, specifically the parasympathetic nervous system and the subsequent reduction of 
exocrine secretions and of gastrointestinal peristalsis. It also has central effects by the inhibition 
of cholinergic transmission in the vestibular region and the inhibition of muscarinic receptor 
located in the medulla oblongata (Horn et al., 2014; Pleuvry, 2012; RxFiles, 2012).  
 
Medications included in this category are scopolamine and atropine. Scopolamine is a 
central acting anticholinergic agent initially used for the treatment of motion sickness and is the 
most commonly used agent used in this category. This agent has been used recently as an adjunct 
therapy for the prevention and management of PONV (Apfel et al., 2010; Gan et al., 2014). The 
short half-life of this medication requires it to be administered transdermally (Horn et al., 2014). 
A meta-analysis of 25 studies and 3298 patients demonstrated the efficacy of transdermal 
scopolamine for the prevention of PONV, with both early and late patch application (Apfel et al., 
2010).  In another study, a multicenter RCT that recruited 620 participants, the combination of 
transdermal scopolamine and intravenous ondansetron was more effective than ondansetron alone 
in the prevention of PONV within the first 24 hours following surgery but not later. The authors 
reported that the effectiveness of the combined therapy was not associated with adverse  
effects, specifically those associated with the scopolamine patch, suggesting a good tolerance of 
patients to this medication  (Gan, Sinha, Kovac, Jones, & Cohen, 2009; Skolnik & Gan, 2014). 
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2.3.1.6.1. Side effects of muscarinic cholinoceptor antagonists 
 
 Different adverse effects associated with anticholinergic agents have been reported and 
divided into early and late adverse effects. Early adverse effects include dry mouth, blurred 
vision and sedation. Late adverse effects include central cholinergic syndrome and confusion, 
especially in elderly patients with underlying cognitive impairment (Apfel et al., 2010; Gan et al., 
2014; RxFiles, 2012). A meta-analysis demonstrated that the most common associated side effect 
of scopolamine was visual disturbances especially between 24 to 48 hours from the time of the 
application when compared to placebo (45% vs 8% RR 3.35, p-value < 0.001) (Apfel et al., 
2010). 
 
2.3.1.7. Other antiemetic agents  
 
 As described above, one of the anaesthetic agents that have known antiemetic properties 
is propofol, which is used as an intravenous agent for the induction and maintenance of 
anesthesia. Studies have demonstrated that propofol may decrease the incidence of early PONV, 
and it has therefore been recommended by the guidelines for the management of PONV to reduce 
the baseline risk for this complication (Gan et al., 2014).  
 
Other medications that are effective as adjuvant therapies in combination with first line 
antiemetic agents include alpha2-agonists (clonidine), which has weak and short term effects; 
mirtazapine (noradrenergic), an antidepressant that has been shown to delay the onset of PONV 
when combined with dexamethasone; and gabapentin, which has been shown to be effective in 
the prevention of PONV, especially when used in combination with dexamethasone; and 
benzodiazepines (midazolam), which have been shown in anxiolytic comparative studies to be 
effective in the prevention of PONV when used preoperatively and in combination with 
ondansetron or dexamethasone (Gan et al., 2014; Kovac, 2013). 
 
The use of dextrose, orally and intravenously, for the prevention of PONV has been the 
target of several studies, mainly in the adult population. In recent years, this intervention has 
received special attention because of the positive impact during the recovery period on patients 
who undergo elective surgical procedures (Hausel et al., 2005; M. D. Smith et al., 2014). A 
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complete review of the impact of dextrose on the prevention and management of PONV, as well 
as the postulated mechanisms of action of this intervention, are discussed in detail at the end of 
this section.  
 
Table 2-7: Recommended antiemetic preventive and management doses guidelines in adults.    
Antiemetic type Medication Dose Timing 
Serotonin receptor 
antagonists 
Ondansetron 4 mg IV End of procedure 
Granisetron 0.35 – 3 mg IV End of procedure 
Palonosetron 0.075 mg IV  At induction 
Substance P-NK1 
recept. antagonists 
Aprepitant 40 mg per os At induction 
Dopamine receptor 
antagonists 
Promethazine 6.25 – 12.5 mg IV * 
Prochlorperazine 
 
Oral 12.5 – 25 mg q 4h PRN 
IM/IV 25 mg OD 
* 
Metoclopramide 20 mg PO Single dose  
10 – 20 mg IM/IV  
2 hr prior to procedure 
End of procedure 
Antiemetic type Medication Dose Timing 
Corticosteroids Dexamethasone 4 - 5 mg IV At induction 
Prednisone 5 mg * 
Butyrophenones Haloperidol 0.5 to < 2 mg IM / IV * 
Droperidol 0.625 – 1.25 mg IV End of procedure 
Histamine receptor 
antagonists 
Dimenhydrinate 
 
1 mg / kg IV (prevention) 
25 – 50 mg  PO/IV q 6-8 hr 
* 
Promethazine 6.25 – 12.5 mg IV * 
Muscarinic 
cholinoceptor 
antagonists 
(Anticholinergics) 
Scopolamine Transdermal patch Prior evening or 2 h prior 
to procedure 
Atropine 0.2 – 0.6 mg  IM/SC 30 – 60 minutes prior to 
procedure 
 
Adapted from Gan et al. Anesthesia & Analgesia 2014; The Compendium of Pharmaceuticals 
and Specialties (CPS), Canadian Pharmacists Association, 2015                     
* Exact timing of administration was not reported.  
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Table 2-7a: Recommended antiemetic dose prophylaxis guidelines in children.    
 
Antiemetic type Medication Dose Timing 
Serotonin receptor 
antagonists 
Ondansetron a 
 
50 – 100 mcg/kg IV OD 
up to 4 mg 
End of procedure 
Granisetron 40 mcg /kg IV OD 
up to 0.6 mg 
End of procedure 
Tropisetron 0.1 mg/kg IV OD 
0.2 up to 2 mg 
At induction 
Corticosteroids Dexamethasone 150 mcg/kg IV OD  
up to 5 mg 
At induction 
Butyrophenones Droperidol 10 – 15 mcg/kg  IV OD 
up to 1.25 mg 
End of procedure 
Histamine receptor 
antagonists 
Dimenhydrinate 
 
0.5 mg/kg IV OD 
up to 25 mg 
* 
 
Adapted from Gan et al. Anesthesia & Analgesia 2014; The Compendium of Pharmaceuticals 
and Specialties (CPS), Canadian Pharmacists Association, 2015  
* Exact timing of administration was not reported.  
a Approved for prevention of POV in children aged 1 month and older  
 
 
2.3.2 Non-pharmacologic prophylaxis  
 
 
2.3.2.1 Intravenous fluid  
 
 Reducing the baseline PONV risk is important for the prevention and further management 
of this complication. One of the strategies that has shown its efficacy is adequate intravenous 
(IV) fluid hydration in the perioperative period (Gan et al., 2014). Different studies have been 
conducted to identify the best fluid hydration strategy for the perioperative setting and the 
amount that would assist in the reduction of PONV incidence. One of these studies compared two 
different IV fluid infusion rates (10 ml/kg vs. 30 ml/kg) in 141 adult patients undergoing elective 
surgery (Magner, McCaul, Carton, Gardiner, & Buggy, 2004). There was a significant difference 
in the incidence of emesis (25.7% vs. 8.6%) and severe nausea (15.7% vs. 2.9%) with the higher 
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IV fluid infusion rate  (Magner, McCaul, Carton, Gardiner, & Buggy, 2004). 
 
 Other studies in the pediatric population have had similar findings. A RCT of 100 
children randomized into two different IV fluid infusion rates (10 ml/kg vs. 30 ml/kg of Ringer’s 
Lactate) showed a decrease in the incidence of PONV in children who received the higher IV 
fluid infusion rate  (Goodarzi, Matar, Shafa, Townsend, & Gonzalez, 2006). Similar studies were 
analyzed in a quantitative review of 15 trials, which compared conservative IV fluid therapy with 
supplemental (higher IV infusion rate) crystalloid fluid administration. Most of the studies 
showed a significant difference between the groups, favouring the group that received 
supplemental fluid over the conservative fluid group (Apfel, Meyer et al., 2012). This additional 
strategy may contribute to the effective prevention and management of PONV in both adults and 
children. 
 
In view of all that has been mentioned so far, it is evident that research has focused on the 
development of new medications that, acting as agonists or antagonists of different emetic active 
sites, can provide a vast pool of options for the treatment and management of postoperative 
nausea and vomiting.  
 
2.3.3  Current Guidelines for prophylaxis and management of PONV  
 
 Numerous published guidelines for the management of PONV are found in the literature, 
including recently updated 2014 consensus guidelines from the Society for Ambulatory 
Anesthesiology (SAA). This consensus was based on previous guidelines published in 2003 and 
2007 as well as a systematic literature review conducted by the SAA (Gan et al., 2003; Gan et al., 
2007; Gan et al., 2014). The guidelines contain different features of the management of PONV 
and include updated data on risk factor assessment for individuals at increased risk for PONV, 
new treatment options for the management of this condition using single and combined options, 
dosing and optimal timing for antiemetic prophylaxis, and new recommendations on the 
prevention and management of PONV (Gan et al., 2014). All the recommendations are based on 
the level of evidence supporting them and applied as guidelines for evidence-based medicine. 
Evidence Grade (EG) and grade practice recommendation guidelines are delineated in Table 8 
(Centre for Evidence-Based Medicine, Oxford, 2014). 
 44 
Table 2-8: Evidence Grade Practice Recommendations for Therapeutic / Prevention    
               Interventions. 
 
Evidence Grade (EG) Description 
1a Systematic reviews of Randomized Control Trials 
1b Individual Randomized Control Trials  
1c All or none Randomized Control Trials 
2a Systematic review of cohort studies 
2b Individual cohort studies or 
Low quality Randomized Control Trials (< 80% follow up) 
2c “Outcomes” research; ecological studies 
3a Systematic review of case-control studies 
3b Individual case-control studies 
4  Case –series / Poor quality cohort and case-control studies 
5 Expert opinion / based on physiology / “first principles” 
 
 
Adapted from the Oxford Centre for Evidence-Based Medicine, Levels of evidence, 2014  
• Met when all patients died before the Rx became available, but some now survive on it, or 
when some died before the Rx became available, but none now die while on it.   
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2.3.3.1.  Baseline PONV risk reduction 
  
 As mentioned in previous sections, despite differences between adult and children PONV 
risk assessment, the incidence of PONV in both populations increases proportionally to the 
number of risk factors present in an individual (Tables 2-2, 2-3 and 2-4)  (Apfel, Laara, 
Koivuranta, Greim, & Roewer, 1999; Apfel et al., 2012; Bounard et al., 2014). The updated 
guidelines give recommendations on strategies for reducing the baseline risk, including the use of 
regional anesthesia and avoidance of general anesthesia, minimizing the use of nitrous oxide (EG 
1a) and volatile anesthetics (EG 2a), both known risk factors for PONV. Evidence of the negative 
impact of inhalation anesthetic agents as risk factors for PONV was discussed earlier (EG 1a). 
Other recommendations to decrease the baseline risk for PONV include the minimization of 
perioperative opioid use (EG 1a), adequate hydration (EG 1a) and the preferable use of propofol 
as an antiemetic agent for the induction and maintenance of the anesthetic process (EG 1a) (Gan 
et al., 2014). 
 
 One study that demonstrated the efficacy of these recommendations in reducing the 
baseline risk factors for the prevention of PONV was the IMPACT study, which evaluated 6 
strategies for reducing PONV in 5199 participants (Apfel et al., 2004). This study found that the 
combination of propofol given as TIVA and oxygen had additive positive effects in reducing 
PONV risk by 25%.  
 
2.3.3.2. One or two interventions for PONV prevention in adults  
 
 Multiple studies have shown the efficacy of different antiemetic medications for the 
prevention and management of PONV. However, only a few of these medications have been 
approved and recommended as first and second line agents in the current guidelines from the 
SAA (Gan et al., 2014). Evidence on the efficacy of these agents was reviewed previously.  
 
 A RTC comparing different strategies of single and combined agents showed that the 
combination of different antiemetic agents for the prevention and management of PONV had 
favourable outcomes compared to the use of a single agent, especially in patients with more than 
one risk factor for PONV (Apfel et al., 2004; Gan et al., 2014). 5-HT3 antagonists are one of the 
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most commonly used agents in combination with droperidol or dexamethasone, showing better 
results and lowering the incidence of PONV (Apfel et al., 2004). To minimize potential adverse 
effects when medications are combined, dosing adjustments are required. This adjustment is 
reflected in studies where ondansetron was used in combination with dexamethasone, in which 
the maximum recommended dose was lower than the dose recommended when each medication 
was used as a single agent. The dosing relation for each recommended agent (single and 
combined) in children and adults at medium and high risk are listed in Tables 2-9 (Gan et al., 
2014). 
 
 
2.3.3.3.  PONV prophylaxis 
 
 Although prophylaxis for PONV is recommended only for those patients at medium and 
high risk, there is insufficient evidence to support the practice of giving prophylaxis to all 
patients undergoing surgical procedures. For those patients at high risk for PONV, the updated 
guidelines recommend routine prophylaxis with at least two antiemetics from different classes of 
combination therapy to optimize their adjunct effects (Gan et al., 2014). Most studies on 
combined antiemetic therapy have demonstrated the efficacy of ondansetron, dexamethasone or 
droperidol in combination compared to their use as single agents. A systematic review and meta-
analysis of 8 studies and 811 patients showed a trend towards the increased benefit of 
combination therapy over single drug use when ondansetron and droperidol were compared  (L. 
H. Eberhart, Morin, Bothner, & Georgieff, 2000). Another meta-analysis of randomized 
controlled trials that reviewed 33 trials and 3,447 patients demonstrated similar antiemetic effects 
and safety profiles when comparing one of the 5-HT3 antagonist agents with either 
dexamethasone or droperidol  (Habib, El-Moalem, & Gan, 2004). These combination regimens 
were significantly more effective than either medication used as single agent. When 
dexamethasone was compared with six different antiemetic medications, a meta-analysis of 17 
trials and 1946 patients demonstrated that dexamethasone was an effective antiemetic as a single 
agent but also that its antiemetic effect was increased, especially when combined with one of the 
5-HT3 antagonist agents (Henzi et al., 2000).  
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 In children, the same principles for PONV prophylaxis in adults should be followed when 
applying the SAA guidelines as this population is at higher risk for PONV. The presence of risk 
factors in children suggests the use of at least two antiemetic agents from different classes for the 
prevention strategy, which should include a 5-HT3 antagonist agent with dexamethasone as 
recommended by the guidelines, unless a contraindication exists (Gan et al., 2014; Hohne, 2014). 
If the patient presents POV, the guidelines recommend administering a different class of 
antiemetic, which is different from the antiemetic agent used initially for prophylaxis.  
 
 
 
2.3.3.4. Antiemetic therapy for patients who have not received prophylaxis or 
in whom prophylaxis therapy has failed 
 
 Management of patients with established PONV, in whom prophylactic therapy has failed 
or who failed to receive prophylactic therapy can be controversial. The guidelines recommend 
that the treatment for these patients should include the administration of an antiemetic agent of a 
different class than that previously used in the preoperative or intraoperative period (Table 2-9) 
(Gan et al., 2014). In a RCT of 2199 patients who received prophylactic antiemetic therapy with 
ondansetron, the repeated dose of the same antiemetic agent for the treatment of PONV in those 
patients in whom the prophylactic therapy was not successful offered no additional control of this 
complication (Kovac et al., 1999). The SAA guidelines recommend not giving the same 
prophylactic antiemetic agent for the treatment of PONV within 6 hours following the initial 
dose, as it confers no additional benefit (Gan et al., 2014). If patients complain of PONV in the 
immediate postoperative period, measures are recommended, starting by making a complete 
evaluation to rule out any physical or other causes related to medications that were administered 
in the perioperative period (Gan et al., 2014; Hohne, 2014).   
 
If no prophylactic agent is given, a low-dose 5-HT3 antagonist agent should be 
administered in the postoperative period as these agents have been adequately studied for 
established PONV (Gan et al., 2014).  Alternative medications for established PONV include 
dexamethasone, droperidol, promethazine and propofol, the latest being as effective as 
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ondansetron but only for a brief period of time  (Gan et al., 2014; Unlugenc, Guler, Gunes, & 
Isik, 2003). 
 
 Another common circumstance is the late onset of postoperative emesis known as 
postdischarge nausea and vomiting (PDNV), which can occur in 30 to 50% of surgical patients 
after ambulatory procedures (Gan et al., 2014; A. Gupta et al., 2003). This complication is of 
prime importance because patients may not have appropriate medical attention after being 
discharged from the facility. One systematic review of 22 studies and 3,629 patients evaluated the 
efficacy of prophylactic antiemetic to decrease the incidence of PDNV (A. Gupta et al., 2003). 
This review showed that the use of ondansetron (4 mg) or combination therapy with two 
antiemetics decreased the risk of PDNV significantly when compared to a placebo.  
 
Table 2-9: Prophylactic and management interventions for prevention of PONV in patients with  
                 no prevention or low-risk patients.  
 
 Estimated risk for PONV (estimated by risk score) 
Low risk Medium risk High risk 
Interventions for 
prophylaxis 
No prevention  Dexamethasone + 
Ondansetron or TIVA 
Dexamethasone + 
Ondansetron + TIVA 
(Case by case 
decision) 
Interventions for 
treatment  
1.Ondansetron 
2.Droperidol (if 
option 1 not effective) 
1.Droperidol 
2.Dimenhydrinate (if 
option 1 not effective) 
1.Droperidol 
2.Dimenhydrinate (if 
option 1 not effective) 
 
Adapted from Gan et al. Anesthesia & Analgesia, 2014 
 
 
2.3.3.5. Implementation of the guidelines 
 
The guidelines require health care providers in a clinical setting to apply PONV 
management protocols and algorithms to guarantee the adequate prevention and management of 
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this common complication. The SAA has created an algorithm (Fig. 2-5) to be followed as a 
guideline, which starts with the proper recognition of risk factors and the selection of the most 
appropriate management strategy (Table 2-10) (Gan et al., 2014). A study comparing the 
incidence of PONV with the incidence documented by nursing staff found that only 42% of 
PONV cases in the PACU and 29% of PONV cases among admitted patients were recognized 
and documented by nursing staff (Franck et al., 2010). This finding indicates that recognizing 
patients at higher risk for developing PONV and avoiding treating patients until after symptoms 
are present may increase the effectiveness of the antiemetic medications given. 
 
Educational strategies can be associated with an increased implementation of antiemetic 
prophylaxis. A study of 384 patients undergoing elective surgery compared the incidence of 
PONV before and after the implementation of an educational strategy by placing the Apfel’s 
simplified score scale in each chart, thereby allowing nurses to recognize patients at higher risk 
of developing PONV (Sigaut et al., 2010). The study results showed that there was no significant 
difference in the antiemetic prophylaxis administration rate between the overall patient 
populations (before 31.4% vs. after 36.8%). A significant difference was seen on the rate of 
antiemetic prophylaxis administered to high-risk patients, which were identified based on the 
Apfel’s simplified score (before 36.4% vs. after 52.8%). Other studies have shown a suboptimal 
PONV prevention reflected in the low proportion of patients (37%) that received the specified 
antiemetic prophylaxis (Gan et al., 2014).   
 
 The SAA guidelines support the implementation of an antiemetic multimodal prevention 
strategy, which follows protocols that allow anaesthesiologists and healthcare professionals to 
facilitate and standardize the prevention and management of PONV (Gan et al., 2014). A 
prospective, observational study followed 134 patients who underwent elective laparoscopic 
cholecystectomy to evaluate the efficacy of a standardized anaesthesia/analgesia protocol for the 
identification of postoperative complications such as pain and PONV. The results showed an 
incidence of moderate and severe PONV of 11% and 2% respectively and identified pain and 
PONV as predictors of an extended stay in the PACU  (Jensen, Kehlet, & Lund, 2007). Another 
observational study of 500 patients who underwent elective surgery showed that the 
implementation of a standardized anesthetic protocol, including PONV prevention, was effective 
for a prompt and smooth postoperative recovery (Bergland, Gislason, & Reader, 2008). This 
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study shows how multimodal prevention and standardized protocols may improve the 
identification, prevention and management of PONV compared to a strict risk-based approach 
without standardized procedures (Gan et al., 2014). 
 
So far, a clear understanding of the different options in the armamentarium for the 
prevention and management of PONV has been presented. The updated guidelines from the 
Society for Ambulatory Anesthesia provide an important framework not only for the treatment of 
PONV but also for the need to recognize patients at higher risk and our role as healthcare 
providers for the prevention, implementation of guidelines and timely intervention in this 
particular setting.  As discussed above, one of the options for the prevention and management of 
PONV is the use of oral or intravenous dextrose, an intervention that may add safe and positive 
results to the existing armamentarium of antiemetic medications and interventions.  
 
Table 2-10: Pharmacologic combination for POV prophylactic therapy in children and adults. 
 Combination therapy and suggested dose Level of 
evidence 
Adults Droperidol + dexamethasone 
5-HT3 receptor antagonist + dexamethasone 
5-HT3 receptor antagonist + droperidol 
5-HT3 receptor antagonist + dexamethasone + dropedriol 
1a 
1a 
1a 
2a 
Children  Ondansetron 0.05 mg/kg + dexamethasone 0.015 mg/kg 
Ondansetron 0.1 mg/kg + droperidol 0.015 mg/kg 
Tropisetron 0.1 mg/kg + dexamethasone 0.5mg/kg 
1a 
1a 
1a 
 
Adapted from Gan et al. Anesthesia & Analgesia, 2014 
 
2.3.4  Effects of different interventions on glucose metabolism 
 
 Before examining the role of intravenous dextrose in the prevention of PONV, it is 
necessary to review the impact of fasting, surgery and administration of dextrose and other 
medications on the glucose metabolism, as this will assist in explaining theories of the underlying 
mechanism of action and possible antiemetic properties of this intervention.  
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2.3.4.1  Glucose Metabolism 
 
 
 Over recent decades, researchers have investigated the impact of glucose metabolism 
impairment, especially in conditions such as diabetes, leading to a better understanding of the 
physiology involved and possible treatment options.  For this purpose, numerous studies have 
compared glucose metabolism in normal individuals and in diabetic patients, leading to the 
current knowledge in this area.  
 
Plasma glucose concentration is the relation between the glucose that enters the 
circulation balanced by the glucose removal rate from the circulation. The main three sources of 
glucose in the circulation are from the following: intestinal absorption, which depends on how 
fast glucose appears in the circulation after gastric emptying; glycogenolysis (glycogen 
breakdown); and gluconeogenesis produced from lactate, amino acids (alanine) and glycerol 
(fatty tissue) during the fasting period  (Aronoff, Berkowitz, Shreiner, & Want, 2004; Nygren, 
2006).  
 
2.3.4.1.1 Glucoregulatory hormones  
 
 
Glucoregulatory hormones are important for the maintenance of circulating glucose 
concentrations within normal narrow levels. These hormones include the following: glucagon 
(released from the alfa-cells of the pancreas); insulin and amylin (derived from pancreatic Beta-
cells); glucagon-like peptide-1; (GLP-1) and glucose-dependent insulinotropic peptide (GIP) 
(derived from the L-cells of the intestine); epinephrine and cortisol (released from adrenal gland); 
and growth hormone (Aronoff et al., 2004). Although the role of some of these hormones will be 
discussed related to the administration of dextrose, specific details regarding each of these 
hormones and the physiopathology involved in glucose metabolism is beyond the goals of this 
thesis.  
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Glucagon is one of the main hormones involved in the process of hepatic glucose 
production through glycogenolysis and gluconeogenesis during the fasting period. During the 
first 8 to 12 hours of fasting, the main source of glucose is glycogenolysis, whereas 
gluconeogenesis is the principal source during longer periods of fasting (Aronoff et al., 2004). 
These processes are the mechanisms used to maintain plasma glucose levels, as glucose leaves 
the circulation at a constant rate during fasting periods.  
 
In contrast to the main role of glucagon as a regulator of glucose appearance in plasma, 
insulin is one of the main anabolic hormones secreted in response to increased levels of glucose 
and amino acids following a meal, and regulates the use of glucose in the tissues, mainly in the 
skeletal muscles and the adipose tissue, lowering the glucose plasma concentration. This 
hormone also suppresses the endogenous production of glucose (glycogenolysis and 
gluconeogenesis) by its direct action and the paracrine effect suppressing glucagon release. 
Insulin secretion is stimulated by different stimuli that include glucose, which is the most potent 
stimulus of insulin release; increased amino acid plasma concentration released from the 
intestine; and the triggering of the parasympathetic system through vagus nerve stimulation 
(Aronoff et al., 2004).  
 
 
2.3.4.1.2. Fasting and its metabolic effect during surgery 
 
 
 As discussed earlier, glucose metabolism and the resulting glucose plasma levels are 
regulated based on glucose uptake and the kind of stimulus activated. The metabolic adaptation 
of the body to periods of fasting allows the body to maintain normal blood glucose levels to 
provide the energy required for all necessary functions. This situation is seen normally at night 
when natural fasting takes place. Overnight fasting follows a post-absorptive state after the last 
meal is absorbed, lowering glucose levels that stimulate glycogenolysis and gluconeogenesis and 
promoting the entry of neo-glucose into the circulation. In general, liver glycogen is used within 
24 hours and gluconeogenesis is the source of glucose, especially for those tissues that depend on 
glucose for their survival (Nygren, 2006). The lack of substrate present during the fasting state 
stimulates glucagon and catecholamine production, increases tissue insulin resistance, decreases 
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glucose usage in peripheral tissues and reduces insulin levels, which induces the mobilization of 
free fatty acids (FFA) and fatty acid oxidation, resulting in the formation of ketone bodies known 
as ketogenesis  (Fukao et al., 2014; Nygren, 2006; Schricker, Latterman, Wykes, & Carli, 2004).  
 
 Different studies have tried to correlate the energy metabolites as a function of fasting 
time by measuring blood total ketone bodies, blood glucose and FFA. One prospective study that 
compared the metabolic response to fasting in children and adults, found that despite the 
maintenance of similar plasma glucose concentrations within the first 18 hours of fasting among 
participants, children developed rapid and higher concentrations of total ketone bodies compared 
to adults over the initial 30 hours of fasting (p<0.001) (Haymond, Karl, Clarke, Pagliara, & 
Santiago, 1982). Similar results were found when blood lactate was measured, demonstrating 
higher levels in children compared with adults within 6 to 30 hours of fasting (p<0.002). Taken 
together, these results may suggest a direct correlation between the adaptation process in fasting 
states and aging, which can be explained by different characteristics that differentiate infancy and 
childhood from adulthood. These characteristics include higher energy demands as a function of 
body weight during infancy, which decreases more than two times in adulthood, better glycogen 
stores and increased muscle mass during childhood, providing a greater reservoir of protein that 
serves as substrate for gluconeogenesis during the fasting period (Bonnefont et al., 1990; Fukao 
et al., 2014).    
  
 Research on glucose metabolism has been conducted primarily in children with 
symptoms associated with suspected pathologies caused by underlying errors of glucose 
metabolism. The metabolic response in patients with these pathologies is normally evaluated by 
implementing controlled fasting tests, which are also used in research and associated study 
protocols. In a prospective study that included 48 children who were referred for metabolic 
evaluation and 11 children with underlying known inherited hypoketotic or hyperketotic related 
conditions, all participants underwent fasting for a 24-hour period (Bonnefont et al., 1990; Fukao 
et al., 2014). Results showed that younger children (1 – 7 years) had higher values of plasma 
ketone bodies and lower levels of glucose when compared to older pediatric patients, 
demonstrating that after 15 hours of fasting ketosis developed faster in younger children than in 
older children. Similar findings were described in a prospective study that included 167 children, 
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showing that patients younger than 7 years of age had lower plasma glucose levels and higher 
levels of total ketone bodies and FFA (van Veen et al., 2011).  
 
 Similar to the results of glucose metabolism in fasting periods, surgery is characterized by 
insulin resistance, which is developed shortly after the start of a surgical procedure and becomes 
more pronounced, particularly soon after the end of the procedure (Nygren, 2006).  This 
characteristic impairment of insulin sensitivity may be the result of the perioperative elevation of 
counter regulatory hormones, glucagon and cortisol seen in situations of increased metabolic 
stress, including surgery (Schricker, Lattermann, Fiset, Wykes, & Carli, 2001). Different studies 
have demonstrated that insulin sensitivity was reduced by 50% in otherwise healthy individuals 
after uncomplicated elective surgery (open cholecystectomy), which was directly proportional to 
the extent and magnitude of the surgical procedure (Thorell, Nygren, & Ljungqvist, 1999). In 
addition, studies have shown that insulin resistance leads to elevated insulin and glucose plasma 
levels secondary to an increased gluconeogenesis response. This response can be attenuated by a 
reduction of about 50% of postoperative insulin resistance when preoperative fasting is avoided, 
as shown in different studies involving the administration of preoperative glucose (Nygren, 
2006).  
 
Previous studies have shown a negative effect of insulin resistance by increasing 
postoperative complications in patients with type 2 diabetes with associated hyperglycemia  
(Behdad, Mortazavizadeh, Ayatollahi, Khadiv, & Khalilzadeh, 2014). It has been suggested that 
measuring insulin resistance following elective surgery could provide information on the degree 
of metabolic disturbance caused by the surgical procedure and provide a parameter of the length 
of stay, which has been found to have a significant correlation with the degree of insulin 
resistance (Thorell et al., 1999). A prospective study by Hahn et al. (2013) showed different 
results in 52 non-diabetic patients with insulin resistance prior to surgery who had an apparent 
lower incidence of postoperative complications, especially lower postoperative nausea and 
vomiting and fewer episodes of hypotension compared to those patients with no insulin 
resistance. Insulin resistance was calculated after the implementation of an intravenous glucose 
tolerance test during the preoperative fasting period of all participants (Hahn & Ljunggren, 2013) 
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However, compared to the reduced metabolic rates seen during fasting, the metabolic 
response during surgery is increased. The catabolic response triggered by conditions that increase 
metabolic stress, including surgical procedures and trauma, is characterized by an elevated 
substrate oxidation and the resulting glycogen, lipid and protein breakdown, leading to 
subsequent loss of body protein as substrate for the production of neo-glucose during the 
gluconeogenesis process. A prospective study that assessed the associated dynamic changes of 
glucose and protein metabolism during surgery in 12 patients found that independent of the 
anesthetic technique (desflurane vs. IV propofol), there was a decreased rate of protein synthesis 
and associated whole protein breakdown, decreased aminoacid oxidation and glucose production, 
and reduced glucose clearance (Schricker et al., 2001).      
 
 Hyperketonemia associated with gluconeogenesis during the fasting period has been 
shown to increase total ketone bodies levels, specifically blood acetoacetate (1.0 mmol/L) and 
hydroxybutyrate (2-3 mmom/L) However, a similar response has not been demonstrated during 
surgery, as prospective studies have shown that mild hyperketonemia was evident at 2 hours 
following abdominal surgery with concentrations documented below 0.5 mmol/L (Schricker et 
al., 2001). These findings may suggest that elevation of total ketone bodies in plasma may be 
most likely associated with the fasting metabolic effect during the preoperative period rather than 
with a direct effect from the increased metabolic stress related to the surgical procedure.  
   
  Preoperative fasting has been the focus of multiple studies seeking to determine not only 
its metabolic effects, as discussed previously, but also the appropriate timing for fasting to 
optimize patient preparation and avoid perioperative vomiting and possible pulmonary aspiration. 
 
 
    2.3.4.1.3 Preoperative fasting conditions and guidelines  
 
 Numerous recommendations and guidelines have been published to determine the 
appropriate fasting period in healthy patients needed to ensure complete gastric emptying prior to 
an elective operative procedure. According to the American Society of Anaesthesiologists (ASA) 
guidelines, preoperative fasting is defined as “a prescribed period of time before a procedure 
when patients are not allowed the oral intake of fluids or solids” (American Society of 
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Anesthesiologists, ASA., 2011). These guidelines were initially published in 1999, when 
concerns were raised about the risk of perioperative pulmonary aspiration (American Society of 
Anesthesiologists, ASA., 2011; Longnecker et al., 2011; Maltby, 2006). This condition is defined 
as the aspiration of gastric contents that may occur after the anesthetic induction, either during 
the procedure or during the immediate postoperative period. Perioperative pulmonary aspiration 
may have detrimental consequences, including aspiration pneumonia, respiratory complications 
and airway compromise (American Society of Anesthesiologists, ASA., 2011; Longnecker et al., 
2011). 
 The first studies looking at preoperative fasting times date to the 1970s, when complete 
NPO “nil per os” fasting after midnight was mandated (Maltby, 2006; Roberts, 2013). Some 
researchers focused their attention on gastric emptying after the ingestion of fluids or solids. A 
RCT demonstrated that in healthy patients, complete gastric emptying after the ingestion of clear 
fluids required a period of 2 hours to pass through the stomach, and that the residual gastric 
volume was not different to that of patients who had ingested fluids 2 hours or 12 to 16 hours 
before the procedure (Maltby, 2006). It was also reported that because of the difference in 
processing solid food based on the size and quantity of the particles ingested, gastric emptying 
takes longer. This was confirmed by measuring the food processing time until the stomach was 
completely emptied following the ingestion of a light meal compared to indigestible food, which 
lasted for a period of 4 and 6 to 12 hours, respectively  (Maltby, 2006; Worobitz & Pounder, 
1985). 
 
 A meta-analysis of randomized controlled trials showed that for clear fluids, preoperative 
fasting periods of 2 to 4 hours accounted for smaller gastric volumes and higher pH values (> 
2.5) compared to those patients with fasting periods restricted to more than 4 hours prior to the 
procedure. In children, similar findings were shown when the same fasting periods were 
compared (American Society of Anesthesiologists, ASA., 2011). Regarding breast milk and 
infant formula, there is insufficient literature to evaluate the appropriate timing for fasting prior to 
a procedure (American Society of Anesthesiologists, ASA., 2011; Cook-Sather, Harris, 
Chiavacci, Gallagher, & Schreiner, 2003). The literature on preoperative fasting failed to show 
any effect of the preoperative fasting period in the incidence of emesis or pulmonary aspiration 
(American Society of Anesthesiologists, ASA., 2011). 
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 The updated 2011 ASA preoperative fasting guidelines are shown in Table 2-11. These 
guidelines were revised and published based on the evidence from current literature, forum 
commentary, clinical feasibility data and expert opinion. They are intended for healthy adults and 
children undergoing elective surgical procedures.  
 
Having discussed the main indications and guidelines for preoperative fasting, I will now 
discuss different interventions that may have a potential effect on glucose metabolism in patients 
undergoing general anesthetic and surgical procedures.  The effects of perioperative glucose 
administration, including its potential antiemetic effect, are discussed in a subsequent section.   
 
Table 2-11: Preoperative fasting guidelines based on type of fluid or food ingested. 
Type of liquid/food Fasting period Important factors 
Clear fluids 2 hours The type of fluid ingested is more important than 
the volume of fluid ingested.  
Breast milk 4 hours  For neonates younger than 44 weeks and infants. 
Infant formula 6 hours For elective procedures requiring general 
anesthesia, sedation (monitored anesthesia care) 
or regional anesthesia.  
Solids and non-human milk 
 
* The amount of non-human milk 
ingested must be considered, as it is 
similar to solids on gastric 
emptying. 
6 hours 
 
8 hours or more 
For light meals or non-human milk. 
 
For fried or fatty foods or meat as they may 
prolong gastric emptying. 
 
    
ASA guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk 
of pulmonary  aspiration: application to healthy patients undergoing elective procedures. Adapted 
form the American Society of Anesthesiologists, ASA, Anesthesiology, 2011. 
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2.3.4.1.4. Effect of anesthetic medications on glucose metabolism 
 
Several animal studies have shown the effect of volatile anesthetics on glucose 
metabolism, mainly the impairment of glucose tolerance by decreasing insulin sensitivity. In vivo 
studies have also suggested that one of the possible mechanisms for volatile anesthetic action on 
impairment of insulin sensitivity is the direct inhibition of insulin secretion by pancreatic B-cells 
when volatile anesthetics are used, specifically halothane, isoflurane and enflurane. These results 
were also observed in a prospective study performed in 30 patients using sevoflurane based 
anesthesia, which demonstrated that stress hormone levels are not affected by the administration 
of this medication, and confirming, in part, the direct insulin secretion inhibition theory  (Tanaka, 
Nabatame, & Tanifuji, 2005). In the study, the metabolic response was triggered by an 
intravenous glucose tolerance test, administered prior to the surgical stimulation. This study also 
suggested that glucose intolerance observed during the anesthetic period without surgical 
stimulation is independent of the anesthetic dose. Furthermore, the authors believed that the 
increased catecholamine levels following endotracheal intubation could contribute to higher 
glucose and lower insulin plasma levels, the later related to impaired insulin secretion caused by 
both volatile anesthetics and the catecholamine effect. 
 
When volatile anesthetics were compared with propofol anesthetics, study results were 
not homogeneous. A study performed in animals demonstrated two main differences between 
volatile anesthetics and propofol: first, sevoflurane was found to attenuate insulin secretion 
induced by glucose plasma levels, whereas propofol was found to enhance insulin secretion; 
second, sevoflurane did not impair insulin sensitivity, whereas propofol did appear to do so (Sato 
et al., 2013). Another animal study using an intravenous glucose tolerance test to stimulate a 
metabolic response in rhesus monkeys showed that when propofol was used for sedative 
purposes, an increase of insulin secretion was demonstrated with increased glucose levels, which 
were normalized as expected after the glucose infusion was completed (Kim et al., 2014). 
Compared to animals that did not receive any type of sedation it can be suggested that the main 
differences between groups were stimulated in part by the physical stress that was relieved in the 
sedated animals. Although these results cannot be extrapolated to humans, they do suggest that 
other factors, including increased metabolic stress, influence the physiological response among 
individuals. 
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A study performed in humans showed different results by measuring the catabolic 
response during surgery, comparing both volatile anesthetics (desflurane) and propofol (Schricker 
et al., 2001). The study failed to demonstrate any significant difference between groups when 
different metabolic parameters were compared, including glucose production and clearance, 
protein breakdown and aminoacid oxidation. After comparing anesthetic based groups, 
endogenous glucose production as well as glucose clearance were both decreased and an 
increment in glucose and cortisol plasma levels was demonstrated. 
 
Further studies are necessary to elucidate the exact mechanism and metabolic response 
that different anesthetic techniques have on healthy individuals. As far as stimulants affecting 
glucose metabolism associated with the perioperative period are concerned, multiple factors 
influence the patient’s metabolic response, including the anesthetic technique, magnitude and 
extent of the surgical procedure, as well as underlying medical conditions. 
 
In addition, it is important to discuss the role of glucose administration and its different 
metabolic and postoperative effects during the perioperative period. 
 
2.3.4.1.5 Intravenous dextrose containing solutions and its effect on glucose 
   metabolism 
 
It is important to clarify that dextrose is the natural form of glucose also known as D-
glucose, and is the term used for the commercial intravenous fluid solutions containing glucose. 
For the purpose of this thesis the term dextrose will be used to reference intravenous solutions 
containing glucose, and the term glucose to refer to blood sugar and its metabolism.   
 
Questions have been raised about the possible metabolic responses to intravenous 
administered dextrose containing solutions and its effect on glucose metabolism. One of the first 
studies performed in 1979 included 12 participants who were evaluated during controlled fasting 
conditions and received a dextrose infusion with or without insulin infusion. Results showed that 
the main method used by the organism to regulate glucose plasma levels among individuals was 
the adjustment of the endogenous glucose production, rather than the variations in tissue glucose 
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uptake, affected by insulin sensitivity  (Wolfe, Allsop, & Burke, 1979). More recent studies have 
supported these results, including a prospective study of 14 patients who received a dextrose 
infusion during general anesthesia, whether or not the surgical procedure was elective(Schricker 
et al., 2004). Results demonstrated that the administration of dextrose, attenuated among patients 
who underwent surgery, reduced endogenous glucose production in all participants. Similar 
increases in plasma glucose levels and plasma insulin concentration also evidenced the inhibitory 
effect of exogenous dextrose over endogenous glucose production when groups were compared. 
 
Another effect of dextrose solutions administration is the volume change among the fluid 
compartments of the body affected by the osmotic transportation of water into the intravascular 
compartment with a subsequent increase in intravascular blood volume that moves glucose into 
the cells. This volume increment change is reversed after glucose is rapidly metabolized into the 
tissues and its osmotic effect is eliminated. A study comparing three different intravenous 
solutions --  dextrose 2.5%, dextrose 5% and Ringer’s Lactate -- showed that plasma glucose and 
insulin concentrations increased as expected in the dextrose solutions compared to Ringer’s 
solution  (Sjostrand, Edsberg, & Hahn, 2001). The volume effect of the solutions compared to 
Ringer’s was similar, assuming that dextrose solutions are never used as volume expanders. A 
slight rebound hypoglycemia effect took place in patients who received dextrose 5%, similar to 
that reported in patients who experienced a sudden discontinuation of parenteral nutrition. 
 
Hypoglycaemia is one of the possible effects of fasting, which, although uncommon, may 
have detrimental consequences. In children, the reported incidence of hypoglycaemia in fasting 
patients is up to 31% among studies, a percentage that is considered even higher in infants. To 
prevent hypoglycaemia, glucose solutions are used perioperatively. Such solutions do not exceed 
an infusion rate of 300 mg/kg/h (4-6 mg/kg/min), representing the basic glucose production in 
pediatric patients. This target glucose content for intravenous dextrose solutions may assist in the 
prevention of hyperglycaemia, allowing the effective management of possible low glucose 
plasma concentrations, especially in fasting patients with subsequent lipid mobilization and 
ketogenesis. Hyperglycaemia may induce diuresis and associated fluid imbalanced from 
dehydration, mostly in patients with increased glucose levels for prolonged periods  
(Leelanukrom & Cunliffe, 2000). 
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Acute postoperative hyponatremia, defined as “a decline in serum sodium within a 48-
hour period to less than 130 mmol/L”, is another possible adverse effect after fluid infusion using 
hypotonic solutions (Carr, Cornish, Predy, & et, 2009). Furthermore, severe hyponatremia is 
most commonly seen in infants when plasma sodium concentrations reach levels below 125 
mmol/L  (Hongnat, Murat, & Saint-Maurice, 1991). Acute hyponatremia is associated with 
neurologic manifestations following the abrupt change in sodium concentration, the movement of 
electrolyte-free water into the brain cells and subsequent cerebral edema. Children and infants are 
more vulnerable to these changes and early signs of acute hyponatremia may be difficult to 
recognize, although, children develop these symptoms earlier, compared to adults, as they have 
limited space and room for brain cells to swell. Early signs and symptoms of acute hyponatremia 
may range from non-specific (headache, nausea, vomiting, confusion and somnolence) to 
respiratory depression, seizures, coma, brain herniation and death (Carr et al., 2009; Hongnat et 
al., 1991).  
 
Prevention of hyponatremia can be obtained by providing adequate maintenance IV 
fluids, however experts relate to the fact that for children, there is no consensus on an ideal IV 
maintenance solution to be used. Therefore, especially in younger patients, different measures 
should be in place to avoid this potential complication, including knowledge of local guidelines, 
adequate record and documentation of fluid balance in hospitalized patients. In addition, it is 
crucial to use balanced salt isotonic solutions, as those are closer to the extracellular composition, 
instead of hypotonic solutions such as dextrose containing solutions in water, which lack 
appropriate balanced electrolyte composition (Carr et al., 2009; Hongnat et al., 1991).   
 
The previous discussion indicates that different interventions in the perioperative period 
can potentially inhibit or promote glucose metabolism during the fasting or postprandial periods. 
These interventions may also affect the fluid or electrolyte balance necessary to maintain an 
adequate body response during periods of increased metabolic demands. 
 
In the following paragraphs, the discussion will focus on the potential effects of 
perioperative carbohydrate administration associated with the recovery period. 
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2.3.4.2. Effect of perioperative carbohydrates on the recovery period 
 
 
There is evidence that dextrose administration may improve recovery outcomes in 
patients undergoing surgical procedures. Research to evaluate outcomes has focused on the 
implementation of protocols using oral or intravenous carbohydrates at any time during the 
perioperative period. 
 
 
2.3.4.2.1 Oral carbohydrates in the perioperative period 
 
 
As discussed previously, preoperative fasting and surgical stress have common significant 
consequences for glucose metabolism, especially for insulin resistance, which can be reduced by 
avoiding preoperative fasting and administering dextrose intravenous infusions or oral glucose 
supplements. The principal behind this intervention relies on the possible effects of metabolic 
response to fasting and surgery, a reduction of catabolic metabolism and of insulin resistance, 
improved metabolism and strength of muscle fibres and the potential effects on overall 
postoperative recovery  (Henriksen, Hessov, Vind Hansen, Haraldsted, & Rodt, 2003). 
 
Multiple studies have focused on determining the adequate glucose administration, dose 
and timing of this intervention. A RCT included 127 participants who underwent elective 
laparoscopic surgery and were allocated to either fast or consume 400 ml of placebo or a 
carbohydrate drink, both given in the morning prior to the procedure. Results showed that the 
incidence of PONV was similar among groups in the first 12 hours, but the incidence increased in 
the fasting group during the following 12 hours, suggesting that the administration of oral 
carbohydrates may reduce PONV after laparoscopic cholecystectomy (Hausel et al., 2005). 
 
The use of oral carbohydrate containing fluids may increase the gastric volume prior to 
surgery, increasing the risk of postoperative vomiting and pulmonary aspiration, an argument 
against the establishment of this practice. A RCT that included seventy patients showed that the 
administration of oral glucose solutions preoperatively did not increase the gastric volume or the 
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gastric pH in participants compared to those who underwent a preoperative fasting period (Yagci 
et al., 2008). Another prospective study that enrolled 60 patients evaluated the postoperative 
recovery outcomes after the administration of oral glucose before and after the surgical procedure 
when compared with preoperative fasting. The study showed an increase in gastric volume in the 
control group and an increment of the gastric pH in the intervention group, suggesting that the 
difference in carbohydrate solution composition and different fasting times may have influenced 
these results. Results also failed to demonstrate any difference in the incidence of postoperative 
nausea, but overall showed that preoperative carbohydrate solutions reduced postoperative 
discomfort including thirst, weakness and anxiety  (Yildiz, Gunal, Yilmaz, & Yucel, 2013). 
 
These results were supported by a Cochrane review that included 27 RCT and 1976 
participants, comparing the use of preoperative carbohydrate solutions with the use of placebo or 
fasting and their influence on postoperative recovery. Results of 14 studies (913 participants) 
demonstrated that the administration of carbohydrates prior to surgery did not increase the risk of 
aspiration pneumonitis, or the risk of postoperative complications when compared with placebo 
or fasting. Differences were also shown when the length of hospital stay was evaluated in 19 
trials (1351 participants), showing that hospital stays were shorter when carbohydrates were used 
compared with placebo or fasting. No conclusive difference in the incidence of postoperative 
nausea or vomiting was found in this meta-analysis (M. D. Smith et al., 2014). 
 
Overall, the use of oral carbohydrate solutions in the perioperative period has shown to be 
safe and beneficial for improving postoperative recovery, although its use has shown 
inconclusive results for decreasing the incidence of PONV.  Despite not being associated with 
increased aspiration pneumonitis, many clinicians continue to be reluctant to use preoperative 
glucose and prefer to maintain their practice by implementing clear guidelines on preoperative 
fasting. This response has led researchers to evaluate the administration of intravenous dextrose, 
instead of oral administration, and its association with the prevention of PONV. 
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2.3.4.3. Intravenous dextrose for the management of PONV 
 
There has been recent renewed interest in the use of intravenous dextrose containing 
solutions for the prevention and management of PONV. The safe and longstanding use of 
dextrose containing crystalloid solutions as part of the resuscitative fluid therapy in pediatric 
patients with significant dehydration has been associated with the stimulation of insulin 
production, faster ketosis and vomiting resolution  (Reid & Losek, 2009). These observations 
have led clinicians to inquire about the relationship of intravenous dextrose containing solutions 
to an enhanced overall postoperative recovery especially for the prevention of PONV. 
 
Studies evaluating the potential effect of dextrose containing solutions have shown mixed 
results. A prospective study of 108 adult patients failed to demonstrate any significant difference 
in the incidence of PONV when comparing an intravenous compound sodium lactate with a large 
dextrose concentration (50%) with a similar intravenous compound without dextrose (McCaul et 
al., 2003). Further studies evaluated these results by changing the intravenous solutions 
administered, as seen in a RCT that enrolled 162 participants who underwent outpatient 
gynaecologic, urologic or breast surgical procedures. This RCT compared the use of intravenous 
Ringer’s Lactate, with or without dextrose 5% administered during the anesthetic emerge phase. 
The study also showed mixed results in the incidence of PONV in the early postoperative period 
(2hr), and an intergroup difference of 3.4% in the incidence of PONV during the first 24 hours 
following the surgical procedure, with a lower incidence in the intervention group compared to 
the placebo group (Patel et al., 2013). 
 
Similarly, another RCT performed of gynaecological adult patients, including 62 
participants, compared the administration of Ringer’s Lactate with or without dextrose 5% 
solution administered at the end of the surgical procedure. Although the incidence of 
postoperative nausea was not significantly different between groups (p>0.05), a decreased use of 
antiemetic rescue medications in the recovery period (p = 0.02) was demonstrated along with a 
significant shorter length of stay in the recovery area (PACU) (p=0.03) (Dabu-Bondoc et al., 
2013). These studies suggest that there is a relationship between the use of intravenous dextrose 
containing solutions and postoperative recovery in patients undergoing ambulatory, elective 
procedures. 
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The present clinical trial resulted from reviewing the above-mentioned studies, which 
evaluated the possible benefits of intravenous dextrose-containing solutions for the prevention 
and management of PONV in adults, and the realization that, to date, studies evaluating this 
intervention in the pediatric population are lacking. Despite the minimal understanding of the 
mechanism of action behind the possible benefit of this intervention for the prevention of PONV, 
intravenous dextrose solutions continue to be available, inexpensive and well tolerated by 
patients. The next chapter describes methodology used for the present study, outlining the 
process and execution of the clinical trial. 
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CHAPTER 3 
METHODS 
 
This chapter describes the methodology of the study, outlining the methods from the 
study design through the study population selection and ethical considerations to data collection 
processes and analysis.  
 
3.1 Study population 
 
The study population consisted of 290 otherwise healthy children who met the inclusion 
criteria as follows: male or female sex; aged three to nine years; minimal preoperative risk based 
on the American Society Anesthesiologists physical status (ASA) I and II (Table 2-4) and 
confirmed by the anesthesiologist the day of the dental procedure; and patients who underwent 
ambulatory dental procedures under general anesthesia from December 2013 to August 2014 at 
Prairieview Surgical Centre in Saskatoon, Saskatchewan, Canada.   
 
A sample size of 284 participants was calculated based on the null hypothesis that the 
early POV rate in the intervention group would be 7.5% or more (non-inferiority based on 
clinical judgement and literature review) than the control group, with a reference of early POV 
rate in the control group 25% (Yun-Dun, 2014; Shen Y, Chen C, Wu C, Cherng Y, Tam K, 
2014).  A confidence interval (CI) [0.14, 0.36], a power of 0.8 (80%), and 5% significance (two-
sided alpha of 0.05) (Table 3-1) was used for the calculation.  
 
3.1.1 Exclusion criteria 
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The exclusion criteria included children under three and over nine years of age, any 
underlying pro-emetic disease, a personal history of diabetes, a positive personal or familial 
history of POV, and those concurrently taking antiemetic medications at the time of recruitment. 
From the 300 eligible participants, 10 children were excluded from the study, nine with a first-
degree family history of PONV and one with a prior personal history of PONV. 
 
Table 3-1. Sample size parameters.  
 
Control 
PONV 
Incidence 
Confidence Interval (CI) 
Sample size group n Total N 
Lower limit Upper limit 
0.3 
0.25 0.35 716 1432 
0.225 0.375 316 632 
0.2 0.4 177 354 
0.25 
0.20 0.30 640 1280 
0.175 0.325 274 548 
0.14 0.36 142 284 
0.2 
0.15 0.25 547 1094 
0.125 0.275 242 484 
0.1 0.3 136 272 
           N= total population size;  n= group size.   
           Parameters: Alpha = 0.05   (two sided)            Power = 0.8 (80 %) 
 
3.2. Ethical considerations 
 
This study was approved by the Ethics Review Board of the University of Saskatchewan 
(Bio# 13-163 – Appendix A) and was registered at Clinical Trials / U.S. National Institutes of 
Health (NCT 01912807 – Appendix B).  
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3.3 Study design  
 
This was an interventional prospective non-inferiority study allocated as a Randomized 
Controlled Trial with parallel assignment of participants. Participants, caregivers, healthcare 
providers and clinical investigators were blinded to group assignment throughout the 
perioperative period. 
 
The randomization, consisting of 50 blocks with six patients each, was performed by the 
Clinical Research Support Unit, College of Medicine, University of Saskatchewan, prior to 
commencing the study.  
 
Allocation concealment was performed by giving an opaque envelope to the 
anaesthesiologist, which contained the corresponding group code (A or B) for the patient based 
on the randomization performed previously.  
 
3.3.1 Study protocol 
 
3.3.1.1 Recruitment of participants and consent process 
 
 In this specific population, due to the nature of the dental procedure (cleaning and/or 
extractions) and the minor risk in this healthy population (ASA I and II), patients were not seen 
prior to the day of surgery, as standard protocol.  Patients were referred directly by their dentist, 
pediatrician or family doctor; none of the patients contacted the surgeon prior to the day of dental 
procedure; and many of them had to travel from outside the city for the procedure. These factors 
made it difficult to contact patients and parents or legal guardians before the day of the dental 
procedure or to contact them through the surgeon’s office. Because of the difficulty of contacting 
the patients or their families in advance, consent was obtained the same day of the procedure. 
 
The day of procedure, all patients were assessed in the waiting room by the 
anesthesiologist confirming the patient's low operative risk and by the surgeon prior to the 
procedure.  Prospective participants and their parents or legal guardians were also contacted by 
one of the researchers in the waiting area approximately one hour before their child was taken to 
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the Operating Room for the dental procedure. The parents or legal guardians and the participant 
were left for a few minutes after the study objectives, purpose and enrolment implications were 
explained. They were provided with a copy of the consent form and a brochure containing 
general information about the study (Appendix C, D and E). Shortly after this, the researchers 
met again with the participant and parents or legal guardian to answer all their questions. At this 
time, the families decided whether to participate in the study. After participation was confirmed, 
consent was signed by the parent or legal guardian and assent was given by the patient (when 
considered capable to assent); as well, demographic data was collected from parents or legal 
guardians (Appendix F). 
 
3.3.1.2 Conduction of the study  
 
In order to maintain the blindness of the study, the solutions were prepared daily by the 
research assistant prior to the recruitment of participants. Ondansetron or normal saline were 
drawn into a syringe (colorless liquid) and coded. The commercial IV infusion bags, either NS or 
D5NS, were covered identically and coded as “A” or “B”.  
 
The subjects were allocated to one of two groups based on antiemetic prophylaxis: the 
intervention or control group. The intervention group (144 participants) received dexamethasone 
(0.15 mg/kg IV maximum 5 mg) and intravenous 5% dextrose in 0.9% normal saline (D5NS) 
maintenance fluid; the control group (146 participants) received dexamethasone (0.15 mg/kg IV 
maximum 5 mg) and ondansetron (0.05 mg/kg IV maximum 4 mg). All doses were based on the 
recommendations from the guidelines for ambulatory anesthesia for children (Gan et al., 2014). 
 
The randomization assignment was given to the research assistant who prepared the study 
drug in advanced (ondansetron vs. normal saline) in identically appearing clear syringes (study 
drug “A or B”) and covered the commercial labeling on intravenous solutions (NS vs. D5NS) in 
the same manner. Kits were made before patient recruitment for each of the groups (control and 
intervention) with the necessary elements for the study (IV maintenance solution bag and clear 
syringe), with the exception of dexamethasone, which was given by the anaesthesiologists from 
the anaesthesia medications stock, according to antiemetic recommended weight-based doses 
(Gan et al., 2014). The research assistant was the only one who knew the code in order to 
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maintain the blind nature for the rest of the participants.   
 
The IV solution (NS vs. D5NS) was placed in a Hospira – Abbott plum A+ IV infusion 
pump (Plum® A+ Infusion System, Hospira Inc, Lake Forest, IL) by the research assistant, and 
the infusion rate was calculated based on the patient’s weight and the “4-2-1” rule for 
maintenance fluid (Meyers, 2009).  Once IV access was established with an IV line containing 
Ringer’s Lactate and the patient was intubated, the maintenance solution was connected and 
infused throughout the operative period. Ringer’s Lactate was available to the anesthesiologists 
to administer as additional fluid as per their preference.  
 
We tried to find a solution for the IV tubing connection by providing a Y connection close 
to the patient’s IV line but found it expensive and not typically required by most 
anesthesiologists.  
 
The protocol was designed so that an envelope would be given to the anesthesiologist 
containing the listed instructions and a table with corresponding dosages for the dexamethasone 
based on the patient’s weight, ondansetron and IV maintenance fluid rate (Appendix G and H, 
respectively).  
 
For the purpose of the study, general anesthetic was defined as the medication induced 
state of loss of protective reflexes and unconsciousness through the administration of general 
anesthetic medications, requiring intubation of the trachea via endotracheal tube (Miller 2010). 
Because there was no standardized protocol for the administration of anesthetic medications, the 
medications given to the patient for the induction and maintenance of the anesthetic procedure 
were chosen and administered at the discretion of the anesthetic provider.  
 
However, the antiemetic medications to be used were those named in the study protocol 
(dexamethasone, ondansetron or study medication). The researcher explained to the 
anesthesiologist that other antiemetic medications were not to be administered as prophylactics. 
There were no modifications to the planned dental procedure. 
 
 
 71 
Figure 3-1. Differences between control and treatment interventions. 
 
 
 
During dental surgery, to make the protocol consistent among participants, the “study 
drug A or B” was administered to the patient by the anesthesiologist at the end of the dental 
procedure, when the dentist removed the throat packing and stopped the IV maintenance solution. 
Any extra IV fluid given during the surgical procedure was continued in the recovery area based 
on the anesthesiologist’s decision. 
 
Once the dental procedure was completed, before the patient emerged from anesthesia and 
extubation and was transferred to the PACU, the anesthesiologist was asked to measure and 
record the blood sugar level using a finger prick blood sample and a meter glucometer 
(AccuCheck aviva ®, Indianapolis USA); this would avoid causing additional pain or discomfort 
to patients by taking the blood sample after the participant was awake. No samples were sent to 
laboratory for testing. The first submitted protocol did not include measurement of blood sugar 
levels. After reviewing different studies and considering our future study analysis, it was decided 
that measuring blood glucose levels after the infusion of maintenance fluids was necessary. Using 
an IV dextrose containing solution would have raised concern about causing hyperglycemia in 
some of the participants. A second amendment was submitted to and approved by the REB 
(Appendix I).  
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The anesthesiologists were not compliant with all the parts of the protocol, as it created an 
extra procedure, adding more time to their main work. Because of this non-compliance, it was 
decided that the research assistant and researcher would become involved in the practical aspects 
of the protocol. This involvement included setting up, connecting, starting and stopping the 
maintenance IV fluids to and from the main IV line, and measuring and recording the blood 
glucose level at the end of the procedure. This improved the anesthesiologists compliance and 
their participation in the study.  
 
After the patients had emerged from the anesthetic and were seen to be stable, they were 
transferred to the Post Anesthetic Care Unit (PACU) for postoperative recovery, where they were 
assessed by nursing staff and remained until they were ready to be discharged based on the Post 
Anesthetic Discharge Scoring System (PADSS) (Ead, 2006) and the institution guidelines.  
 
Nursing staff and researchers assessed the presence of POV and the number of episodes 
of it in the PACU. For the purpose of the study protocol, Postoperative Vomiting (POV) was 
defined as vomiting (expulsion of gastric content) within 24 hours after surgery. In the PACU 
area, the period was accounted and defined as early POV either immediate or within the first 2 
hours after the dental procedure and emerge from the general anesthesia. Late POV was defined 
as presence of vomiting within the 24 hours from the time of discharge from the facility. 
Retching and nausea were not accounted nor recorded as it was difficult for patients to 
communicate and could create confusion on parents or legal guardians.   
 
The initial study protocol included the use of a pictoric Postoperative nausea scale,  
(Baxter, Watcha, Baxter, Leong, & Wyatt, 2011) to measure postoperative nausea. This scale has 
been validated in pediatric cancer patients over seven years of age who are undergoing 
chemotherapy. Since the majority of our patients were under five years of age, this scale was 
unsuitable for use with our study population. Additionally, we observed that patients were 
irritable during the early postoperative recovery, which made the use of the scale an additional 
stress for patients and parents or legal guardians. It was thus decided to avoid the use of this 
instrument and assess patients only by the presence of postoperative vomiting. This assessment 
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tool is reliable and causes less confusion than the scale when used with young children, who find 
it difficult to express the sensation of nausea. 
 
Analgesics and antiemetic agents were prescribed by the anesthesiologist for the recovery 
period and given according to the nursing staff’s assessment and institutional guidelines, which 
provided standardized criteria with the department of anesthesiology. 
 
Follow up of the patient’s recovery and incidence of emesis within 24 hours after 
discharge was done by phone calls made by the researchers (Appendix J). This protocol was 
followed through the duration of the study without any further modifications.  
 
3.4 Data collection 
 
Researchers who collected the data were blinded to group assignment. The primary 
outcome was incidence and the number of episodes of emesis in the PACU (immediate and early 
postoperative period). Secondary outcomes included the following: incidence and number of 
episodes of emesis within 24 hours after discharge; use of rescue antiemetic medications in the 
immediate and late recovery period; intraoperative blood glucose level; unplanned hospital 
admission for POV; delays in discharge from PACU due to POV; and return to hospital or a 
hospital clinic for a medical assessment due to POV. Intraoperative data, including anesthetic 
medications and doses administered, were recorded in the operating room from the anesthetic 
record (Appendix F). 
 
3.5 Statistical analysis   
Statistical analysis was performed with the assistance of the Biostatical Support Unit 
associated with the Department of Surgery (University of Saskatchewan) using SAS software (v 
9.4; SAS Cary, NC, U.S.A.). All analyses were performed on an intention-to-treat basis (S. K. 
Gupta, 2011).  
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Variables were checked regarding assumptions underlying the use of parametric and 
nonparametric statistics and analyzed accordingly. 
To examine the association between categorical variables and primary outcome 
(proportion of participants who presented emesis during the early postoperative period), 
secondary outcomes (proportion of participants who presented emesis during the late 
postoperative period [24 hr]), and antiemetic rescue medication requirement, Chi-square test or 
Fisher’s exact test were used as appropriate. 
Median and interquartile ranges were reported for those continuous variables that did not 
meet normality criteria. Mean and SD were reported for normally distributed variables. Two-
sample T-tests were used to compare the mean between groups (e.g. intervention vs. control) for 
continuous normally distributed variables, including surgical procedure – extractions, procedure 
length, glucose level, amount of IV fluids administered and opioid and anesthetic medication 
dose used.    
Continuous, non-normally distributed variables were compared between randomized 
groups using Wilcoxon tests when analyzing two samples, and Kruskal-Wallis tests when 
analyzing more than two samples. This comparison was used to study the relationship between 
primary and secondary outcomes and the anesthetic agents used for induction and maintenance, 
volume of IV fluid administration and opioid use. 
 
The level of significance was set at 0.05 (two-tailed), which was used as the criterion for 
rejection of the null hypothesis (p >0.05).   
 
3.5.1 Non-inferiority analysis  
To understand why a non-inferiority trial was chosen, it is important to recognize the 
main differences between superiority, equivalence and non-inferiority clinical trials.   The 
primary objective of a superiority clinical trial is to show that the response to a new therapy is 
superior compared to an established standard therapy. In turn, the purpose of equivalence clinical 
trials is to show that the new therapy effect is identical to the standard therapy while in non-
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inferiority trials the purpose is to show that the new therapy effect is not worse when compared to 
the standard therapy (Christensen, 2007). 
In this particular trial, ethical considerations were decisive for choosing to conduct a non-
inferiority study protocol, based on the International Conference on Harmonization’s “Choice of 
control group and related issues in clinical trials” (Food and Drug Administration, U.S., 2010). 
This guideline suggests that an active control (vs. placebo) should be considered in patients with 
a higher inherent risk of developing the condition studied in the trial.  For our analysis, data 
describing the historic effect of the active control was extracted from a randomized control trial 
performed in children with similar demographic characteristics to our study population, which 
assessed the combined, protective effect of both dexamethasone and ondansetron. This study 
described the proportion difference of the combination of these two drugs versus dexamethasone 
alone as 18% (Splinter, 2001). 
Characteristics of this non-inferiority study protocol would allow us to investigate that 
intravenous dextrose containing solutions have a significant effect in preventing postoperative 
vomiting in children. The study design tests if the treatment effect of the intervention (D5NS + 
dexamethasone) is not inferior to the treatment effect of an active control (Ondansetron + 
Dexamethasone). In order to assess the effect difference between the active control (ondansetron 
combined with dexamethasone) and the intervention procedure (D5NS in combination with 
dexamethasone), a non-inferiority margin was calculated a-priori. Our choice of non-inferiority 
(NI) margin was guided by published principles (Food and Drug Administration, U.S., 2010). We 
first reviewed previous published NI margins of therapeutic trials conducted in pediatric 
anesthesia. A recent trial investigating the risk of hemorrhage when dexamethasone is 
administered to children undergoing tonsillectomy used a non-inferiority margin of 5% given that 
the outcome is clinically serious and life threatening (Gallagher, T.Q., et al. 2012). We felt a 
wider NI margin (7.5%) was appropriate for the following clinical reasons: PONV is not a 
clinically important as post tonsillar hemorrhage, D5NS is an inexpensive therapy, and D5NS has 
a long clinical history of safety.  Finally, our chosen margin is less than the expected mean 
treatment effect of a similar dose of ondansetron when combined with dexamethasone (Splinter, 
2001). 
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Having described the patient population, methods and study protocol, I will now move on 
to describe the results of the interventions and data analysis along with a specific non-inferiority 
study analysis.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 77 
 
 
 
 
 
 
 
CHAPTER 4 
STUDY RESULTS 
 
This chapter presents the results of the study including the demographic characteristics, 
the intraoperative anesthetic management and the primary and secondary outcomes. In addition, 
this chapter describes the results from the non-inferiority analysis.   
 
4.1 Main study results 
 
A total of 300 participants were assessed for eligibility to participate in this clinical trial. 
Ten participants were ineligible for not meeting the inclusion criteria. Therefore, data from 290 
patients were enrolled and analyzed as shown in Figure 4-1, based on the 2010 CONSORT group 
report guidelines (CONSORT, 2010).  
 
Demographic characteristics among groups were similar as presented in Table 4-1. There 
was no association between sex and increased incidence of POV (p=0.63). Nor was there an 
association between sex and the type of procedure performed (dental cleaning p=0.18 vs. dental 
extractions p=0.17).  Although ethnicity was not recorded for all participants, there was an 
increased number of patients with indigenous ethnicity compared to the rest of the participants. It 
was noted that participants with indigenous ethnicity had a higher number of tooth extractions 
compared to Caucasians or participants with other ethnic background. Ethnicity was self-reported 
by parents or legal guardians.  
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Clinical trial report based on 2010 CONSORT flow diagram. 
 
 
 
Figure 4-1. Clinical trial report based on 2010 CONSORT flow diagram.  
Adapted from the CONSORT 2010 Flow Diagram, Transparent reporting of trials, 
http://www.consort-statement.org  
 
 
 
 
 
Figure 1. Clinical Trial Report based on 2010 CONSORT flow diagram. 
 
 
 
 
Figure 1. Clinical trial report based on 2010 CONSORT flow diagram.  
     Adapted from the CONSORT 2010 Flow Diagram, Transparent reporting of    
     trials,  http://www.consort-statement.org 
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Table 4-1. Demographic characteristics by group.  
 
Characteristic Intervention Group 
(n=144) 
Control Group 
(n=146) 
Age (months) TT 
     Median (IQR) 
     (years) 
 
55 (21) 
(4.5) 
 
56 (20) 
(4.6) 
Sex n (%) CS 
     Male 
     Female 
 
74 (51.4) 
70 (48.6) 
 
72 (49.3) 
74 (50.7) 
Ethnicity n (%) CS 
     Indigenous   
     Caucasian 
     Other 
     Unknown / not recorded 
 
46 (31.9) 
38 (26.4) 
5 (3.5) 
55 (38.2) 
 
42 (28.8) 
37 (25.3) 
11 (7.5)  
56 (38.4) 
 
IQR   = Interquartile Range; CS = Chi Square ;  TT = t-Test  
 
 
Interestingly, the procedure length and the proportion of patients who vomited varied 
significantly during the early and late postoperative periods. Those patients who underwent 
procedures lasting longer than 60 minutes had a lower frequency of vomiting in the PACU 
(4.9%) when compared to their vomiting incidence during the late postoperative period (12.3%).  
Patients whose procedures lasted less than 30 minutes neither vomited in PACU nor after 
discharge, while the proportion of patients whose procedure lasted between 30 to 60 minutes and 
vomited was consistent at 7.9% in the PACU and 6.8% within 24 hours after discharge.  
 
Despite not having implemented a standardized perioperative anesthetic management 
procedure as part of the study protocol, the distribution of intraoperative anesthetic medications 
used in both groups was similar, as seen in Table 4-2. 
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Table 4-2. Distribution of anesthetic type by group. 
 
Category 
Intervention Group 
(n=144) 
Control Group 
(n=146) 
P value 
Induction        n (%) 
      Volatile (Sevoflurane) 
      Nitrous Oxide 
      Propofol 
 
Maintenance    n (%) 
      Volatile (Sevoflurane) 
      Nitrous Oxide 
      Propofol 
           Single doses 
           TIVA 
 
Induction and  
Maintenance     n (%) 
      Volatile (Sevoflurane) 
      Nitrous Oxide 
      Propofol 
 
144 (100) 
90 (63) 
118 (82) 
 
 
117 (81) 
44 (31) 
58 (40) 
17  (12) 
41  (28) 
 
 
 
117 (81) 
38 (26) 
45 (31) 
 
145 (99.3) 
83 (56.8) 
126 (86.3) 
 
 
118 (80.8) 
46 (31.5) 
63 (43.2) 
13  (8.9) 
50  (34.2) 
 
 
 
118 (80.8) 
39 (27) 
56 (38) 
 
0.13 FT 
0.57 CS 
0.24 CS 
 
 
0.26 CS 
0.46 CS 
0.17 CS 
 
 
 
 
 
0.99 CS 
0.56 CS 
0.23 CS 
CS   = Chi Square        FT= Fisher’s exact test           TIVA = Total Intravenous Anesthesia 
 
 
A positive correlation was found between the use of propofol and a lower proportion of 
patients who vomited. This correlation was more notable during the early postoperative period, 
especially after administration of total intravenous anaesthesia (TIVA) used for anesthetic 
maintenance (p=0.06; no propofol= 7.19%; single dose = 9.68%; TIVA = 1.1%).   
 
Perioperative use of intravenous fluids and opioid medications are reported in Table 4-3. 
No significant difference was found in the amount of intravenous fluids administered to the 
patients in each group. The mean amount of dextrose received by the intervention group after 
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administering D5NS as the treatment solution was calculated as 24.81 mg and a median of 23.5 
mg [17.0 mg – 50.0 mg]. The mean blood glucose levels for the intervention group was 6.3 
mmol/L [3.6 mmol/L – 11.3 mmol/L] and a median of 6.3 mmol/L compared to the mean blood 
glucose levels for the Control group was of 5.5 mmol/L [2.8 mmol/L– 10 mmol/L] and a mean of 
5.5 mmol/L. There was a statistically significant difference in blood glucose levels between 
groups (p = <0.0001), with the mean levels in the intervention group being 0.8 mmol/L higher 
than the active control. The blood glucose levels measured did not consistently correlate with the 
amount of dextrose received as shown in Figure 4-2 and Table 4-3.   
 
  
Figure 4-2. Correlation between dextrose dose and blood glucose levels among  
participants. This figure shows the correlation between dextrose dose (mg) received and 
the blood glucose levels (mmol/L). The dots along the Y axis represent participants who 
did not receive any dextrose (Control group with administered dextrose amount = 0) and 
its corresponding glucose levels. The dots distributed throughout the graphic represent 
participants who received dextrose containing solution during the procedure (Intervention 
group) and its corresponding glucose levels.  
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Opioid was equally distributed among groups as shown in table 4-3. Those patients who 
received morphine were 12 times more likely to vomit in PACU (p = 0.0021, OR = 12) and 10.5 
times more likely to vomit after discharge (24hr, p = 0.0002, OR = 10.5) in the late postoperative 
period. Although not significant (p=0.21), there was a lower incidence of POV in the early and 
late postoperative period associated with the use of Remifentanyl during maintenance anesthetic 
(PACU 1.56 % vs. 24 hr 7.5%) compared with those who did not receive this medication (PACU 
6.7 % vs. 24 hr 12.6%). No significant correlation was seen between fentanyl administration and 
increased incidence of POV in either the early or late postoperative period (p=0.82).   
 
The results of the primary and secondary outcomes can be found in Figure 4-3 and Table 
4-4. In the early postoperative period (PACU), 11 out of 144 (7.64%) participants presented POV 
compared to 5 out of 146 (3.45%) in the control group. Similarly, in the 24 hr postoperative period 
the proportion of participants developing POV in the intervention group was higher with 15 out of 
144 ( 10.4 % ) compared to 9 out of 146 (6.2 %) in the control group. Some patients were lost at 
24 hr follow up, but the number of responses was similar between groups with 75% answered calls 
in both groups.  
 
When combining the total proportion of POV in the intervention and control groups during 
the overall postoperative period (PACU and 24 hr) the total number of patients presenting with 
POV was 23 (20.5%) and 13 (13.7%) respectively. From these, a low number of patients presented 
POV in both early (PACU) and late (24 hr) periods: 3 in the intervention group and 1 in the control 
group; these patients were only included once in the combine total proportion of POV (PACU and 
24hr).   
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Table 4-3.  Procedure characteristics and perioperative IV fluids and opioid use  
distributed by group 
Category 
Intervention Group 
(n=144) 
Median (IQR)      
Control Group 
(n=146) 
Median (IQR)         
P value 
Type of procedure  
n (%) CS 
    Dental Cleaning 
    Dental Extraction  
              Indigenous 
              Caucasian 
              Other 
              Unknown/not  
                   recorded 
    Other (Abscess) 
 
 
49     (34) 
94   (66.0) 
34     (32) 
19   (17.8) 
5    (4.7) 
36   (33.8) 
 
1   (0.7) 
 
 
50     (34) 
96  (65.7) 
35  (33.6) 
19  (18.2) 
7   (6.7) 
35  (33.6) 
 
0 
 
 
0.96 CS 
0.93 CS 
 
 
 
 
 
0.46 FT 
Procedure Length  
(min) TT, WT 
        < 30 min 
        31-60 min 
        > 61 min  
Median (IQR) 
 
 
2 (1.4) 
34 (23.6) 
108 (75) 
80 (38) 
 
 
1 (0.6) 
29 (19.8) 
116 (79.4) 
80 (40) 
0.44 WT 
 Median (IQR)     Range Median (IQR)     Range P value 
  IV Fluids (mL)     
      Total maint.  
      IV Bolus given 
      Total IV fluids  
 
   65.7  (30) 
   250  (150) 
   314.5(162) 
   
(19 – 138) 
(  0 – 600) 
(43 – 778) 
 
65.4  (31) 
250 (172) 
307 (224) 
   
(23.8 – 130) 
(0 – 600) 
(61 – 696.3) 
 
0.75 CS 
0.90 CS 
0.80 CS 
Opioid use  
      Morphine  (mg) 
      Remifentanyl(mcg) 
      Fentanyl  (mcg) 
 
1.95  (0.5)  
0.15 
27.5  (25) 
N (%) 
82 (57) 
41 (28) 
62 (43) 
 
1.7 (0.5) 
0.15 
22.5 (20) 
N (%) 
82 (56) 
46 (32) 
54 (37) 
 
0.14 CS 
0.54 CS 
0.49 CS 
 CS   = Chi Square test       FT = Fisher’s exact test    WT = Wilcoxon non-parametric test 
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                Proportion of postoperative vomiting by group 
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
                               PACU              24 hours follow up  
 
Figure 4-3. Proportion of postoperative vomiting by group.   
Blue bars represent the intervention group. Red bars represent the control group.   
      POV = Postoperative vomiting. PACU = Postanesthetic Care Unit.   
 
 
 
 
 
 
 
 
 
 
Proportion of Postoperative Vomiting by Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Represents the proportion of Postoperative Vomiting by Group.  
Blue bars represent the intervention group. Red bars represent the control 
group.  POV = Postoperative vomiting. PACU = Postanesthetic Care Unit.   
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Table 4-4. Primary and secondary outcomes by group 
 
Outcome 
Intervention 
Group 
(n=144) 
Control 
Group 
(n=146) 
P value 
POV (%) 
• Immediate POV 
• Early (PACU 0-2h) 
• Late (24 h follow up) 
            Answered calls (%) 
            POV  (%) 
• PACU and 24h 
• Any POV (PACU or 24h) 
      Received TIVA 
      No TIVA 
 
0 (0) 
11 (7.64) 
 
108 (75) 
15 (10.4) 
3 (2.2) 
23 (20.5) 
1  (1.38) 
21  (14.5) 
 
0 (0) 
5 (3.45) 
 
109 (75) 
9 (6.2) 
1 (0.7) 
13 (13.7) 
1  (1.36) 
11 (7.5) 
 
 
0.11 CS 
 
 
0.17 CS 
0.36 FT 
0.07 CS 
Antiemetic Rescue Medication   n (%) 
     Early (PACU) 
     Late (24h follow up) 
 
 4 (2.8) 
     2 (1.4) 
 
0 (0) 
0 (0)  
0.059 FT 
Blood Glucose level (mmol/L) 
    Median   (IQR) 
    Mean       (SD) 
    Range 
 
6.3  (1.8) 
6.3  (1.2) 
(3.6 – 11.3) 
 
5.5  (1.2) 
5.5  (1.0) 
(2.8 – 10) 
 
 
< 0.0001TT 
Delayed Home Discharge (%) 2 (1.4) 0 (0) 0.24 FT 
Post-discharge Medical Assessment  0 (0) 0 (0)  
I/M    = Induction or Maintenance;    I and M = Induction and Maintenance;   
POV  = Postoperative vomiting;        PACU   = Post Anaesthetic Care Unit  
CS       = Chi Square                            FT                 = Fisher’s exact test        
TT           = t-test     
IQR   = Interquartile Range               SD         = Standard deviation 
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4.2 Non-inferiority analysis results 
 
In order to assess the difference in response between the active control (ondansetron 
combined with dexamethasone) and the intervention procedure (D5NS in combination with 
dexamethasone), a non-inferiority margin was calculated based on the proportion difference of 
the historic effect of the active control compared to the results of the present study.  
 
Table 4-5. Proportion difference of the active control and the present study (DexPo). 
 
Study 
(N = Total number 
of participants)  
Compared 
groups 
Period Proportion 
of POV (%) 
(in PACU) 
Proportion 
difference 
95% CI 
Historic Effect of 
Active Control  
(N= 193) 
(reference control 
study  
Yun-Dun, 2014) 
Ondansetron + 
Dexamethasone 
n = 111 PACU 
(0 - 2 h) 
5.41 
17.79 % [7.71, 27.82] 
Dexamethasone 
 
n = 82 
23.2 
DexPo  
Study  
(N=289) 
Dextrose + 
Dexamethasone 
n = 144 PACU 
(0 - 2 h) 
7.64 
4.19 % [-1.01, 9.5] 
Ondansetron + 
Dexamethasone 
n = 145 
3.45 
 
The historic effect proportion difference was 17.79%. The Non-inferiority margin was set 
up as an acceptable clinical difference of 7.5%. This was established based on the acceptable 
proportion of POV in patients that would not exceed what was shown in a previous study 
comparing POV proportion difference between participants in the dexamethasone group vs the 
dexamethasone + ondansetron group, as shown in table 4-5 (Yun-Dun, 2014).  
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The proportion difference between the intervention group and active control in our study 
was 4.19%, as shown in Table 4-5. The upper limit of the 95% CI surrounding this proportion 
difference was 9.5, which crossed the non-inferiority margin of 7.5%, as demonstrated in Figure 
4-4.   
 
Figure 4-4 . Non-inferiority analysis of the active control vs. study intervention.  
 
 Fig. 4.4  Error bars indicate the 95% CI (one sided).  
 D=Non-inferiority margin set up as 7.5%      Proportion difference of POV = POV  
proportion of the intervention group minus the POV proportion difference of the 
control group.  A proportion difference that does not exceed the non-inferiority 
margin of 7.5% would demonstrate that the POV proportion in the intervention group 
is not greater than the control POV proportion by more than 7.5%.  
Red dot represents study POV proportion difference between intervention and 
control groups. Yellow dots represent different possible outcomes.  
(Adapted from Schumi, 2011; Food and Drug Administration, U.S. 2010; Piaggio, 
2012).  
 
Figure 10. Non-Inferiority analysis of the active control and study intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 10 Error bars indicate the 95% CI (one sided).  
 '=Non-inferiority margin set up as 7.5%  
Proportion difference of POV = POV proportion of the intervention group minus the 
POV proportion difference f the control group.  
A proportion difference that does not exceed the non-inferiority margin of 7.5% 
would demonstrate that the POV proportion in the intervention group is not greater 
than the control POV proportion by more than 7.5%.  
Red dot represents study POV proportion difference between intervention and 
cont ol groups.  
Yellow dots represent different possible outcomes.  
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The next chapter discusses the implications of the main study findings, the study’s 
strengths and limitations, as well as future directions in this important area of pediatric patient 
care.   
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
The present study was designed to investigate the hypothesis that the administration of 
intravenous dextrose in combination with dexamethasone during the operative period would be 
non-inferior in reducing the incidence of postoperative vomiting (POV) in children undergoing 
dental day surgery under general anesthetic when compared to the standard therapy, ondansetron 
with dexamethasone.  
 
According to the FDA and CONSORT guidelines for analysis and reporting non-
inferiority clinical trials, the position of the confidence interval of the POV proportion difference 
in our study crossed the clinical margin of 7.5% indicating that the results are inconclusive. 
These results led us to conclude that the difference between the active control and treatment is 
nonsignificant and noninferiority cannot be established when intravenous dextrose in 
combination with dexamethasone was compared to ondansetron in combination with 
dexamethasone in preventing POV in surgical pediatric patients. (Food and Drug Administration, 
U.S., 2010; Piaggio, Elbourne, Pocock, Evans, & Altman, 2012).  
 
5.1 Review of the hypothesis 
 
Several reports have shown that postoperative nausea and vomiting (PONV) is one of the 
common complications following surgical procedures among adults and pediatric surgical 
patients (Baines, 1996; Gan et al., 2014; Longnecker et al., 2011). Children are especially at 
increased risk of this postoperative complication with an incidence reported to be twice that of 
adults, that varies between 8.9 and 42% for PONV and up to 80% in surgery-specific cases for 
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postoperative vomiting (POV) (Gan et al., 2014; Kovac, 2013). This high incidence has prompted 
numerous investigations to identify significant associated factors influencing postoperative 
vomiting, evaluate different strategies for the assessment of those patients at higher risk and 
prevent the occurrence of PONV in this specific population. 
 
Previous studies have identified major patient-related risk factors for PONV in children 
including childhood and previous history of PONV as shown in the POVOC score (Bounard et 
al., 2014; L. Eberhart et al., 2004). Additionally, operative risk factors including the type and 
duration of the procedure and the exposure to general anaesthetics and opioids in the 
perioperative period also influence the occurrence of PONV (Apfel et al., 2012; Becker, 2010; 
Bounard et al., 2014; Gan et al., 2014).  
 
 Current guidelines for the prevention and management of PONV in adults and children 
from the Society for Ambulatory Anaesthesia (Gan et al., 2014) recommended the use of 
multimodal approach for the prevention of POV in those with higher risk, based on the additive 
effect of antiemetic drugs acting via different mechanisms as discussed previously(Apfel et al., 
2004). The guidelines also have postulated the importance of education in the identification of 
high-risk patients and the need to establish adequate strategies for the prevention and 
management of this condition. For this purpose, the efficacy of multiple antiemetic medications 
has been studied in adult and pediatric populations, establishing the need for combined antiemetic 
therapy for patients at increased risk, considering the combination of ondansetron and 
dexamethasone as the gold standard when compared with other antiemetics  (Gan et al., 2014; 
Horn et al., 2014; Skolnik & Gan, 2014).  
 
Different new strategies for the prevention of PONV including the use of oral 
carbohydrate solutions in the perioperative period has shown to be beneficial improving 
postoperative recovery, although its use has shown inconsistent results on decreasing the 
incidence of PONV (M. D. Smith et al., 2014).  Despite the safe profile of oral carbohydrate 
solutions and the lack of associated increased aspiration pneumonitis (Hausel et al., 2005; M. D. 
Smith et al., 2014), many anaesthesiologists prefer to maintain their practice by implementing 
clear guidelines on preoperative fasting, avoiding the use of oral glucose containing solution 
preoperatively.  
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Possible benefits of using intravenous dextrose-containing solutions in preference to oral 
solutions for the prevention and management of PONV in adults were evaluated in previous 
studies. Although, the results failed to show any significant difference in the incidence of PONV, 
the use of dextrose containing solutions did decrease the use of antiemetic rescue medications 
and the PACU length of stay when compared to the standard of care therapy (Dabu-Bondoc et al., 
2013; Gan et al., 2014; Patel et al., 2013).  Studies evaluating this particular intervention in the 
pediatric population are lacking. To date, the present study is likely the first to potentially fill this 
gap and offer further insight into the efficacy of intravenous dextrose on the reduction of POV. 
 
5.2 Discussion of the results 
 
When comparing the sample size, patient population characteristics and the demographic 
distribution of our study to previous studies performed in adults evaluating the use of dextrose for 
the prevention and management of PONV, those studies typically involved smaller sample sizes 
ranging from 62 to 121 patients (Dabu-Bondoc et al., 2013; McCaul et al., 2003; Patel et al., 
2013). The larger sample size of 290 participants provided a significant power to our study 
(80%).  
When looking at the ethnicity of the population, a significant number of participants had a 
indigenous background based on the referral made and self-identification by their parents or legal 
guardians (Table 13). A position statement published by the Canadian Pediatric Society  (Irvine, 
Holve, Krol, Schroth, & Canadian Pediatric Society, First Nations, Inui and Metis Health 
Committee, 2011) stated that the oral health of children of First Nations communities is a major 
health issue. This report shows that in some Canadian First nation communities, the prevalence of 
early caries in childhood exceeds 90%, and identifies poverty as the major risk factor. This 
important health issue carries significant consequences including the need for procedures under 
general anesthesia, which are of short effect as relapse and decay recurrence are seen without a 
proper behavioural change in oral hygiene after the first procedure (Irvine et al., 2011).  
 
Similar results were published on a report on the Findings of the First Nations Oral Health 
Survey (FNOHS) published in 2011 by the First Nations Information Governance Centre that 
reported a significant poor oral hygiene in pre-school children (aged 3-5 years) with 85.9% of 
children experiencing caries in the primary dentition. First Nations School age children (aged 6-
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11 years) also presented with a high incidence of caries in their primary dentition (80.4%) and 
permanent dentition (67.1%) when compared with non-aboriginal children (55.2%). Similarly, 
when compared with non-aboriginal children, more First Nations children reported poor oral 
hygiene and increased frequency of pain and food avoidance as a consequence of this oral 
problems (The First Nations Information Governance Centre, 2011).  These reports suggest a 
strong link between the underlying oral health of the participants and the increased number of 
extractions required, as seen on our results with a higher number of participants requiring 
extraction procedures when compared First Nation participants with Caucasian participants (69 
(36%) vs 38 (20%) respectively). 
 
The nature of the study as a randomized controlled trial allowed for an equal distribution 
of participants between groups in relation to main characteristics such as sex, mean age and 
specific considerations for conducting the study including procedure length and anesthetic agents 
used. These considerations were especially important after analyzing the risk of PONV, and 
stratifying participants based on to the Simplified Risk Score for PONV in children as reviewed 
previously (L. Eberhart et al., 2004).   
 
When comparing the association between main risk factors and the incidence of POV in 
children, the results were consistent with data obtained in previous studies (Apfel et al., 2012; L. 
Eberhart et al., 2004; Gan et al., 2014).  Although the type of procedure in the present study was 
not considered at increased risk for POV, lengthier procedures (>30-60 minutes) were associated 
with a higher proportion of vomiting.  
 
Our results in regard to the relationship between POV and anesthetic methods were also 
consistent with data attained in previous studies (Apfel et al., 2002; DeBalli, 2003; Fernandez-
Guisasola et al., 2010). Nitrous oxide was associated with a higher proportion of POV, while the 
use of propofol during the entire procedure (at induction and during maintenance) was associated 
with a lower proportion of POV (OR = 0.28). Given that the anesthetic technique was not 
standardized, there was potential for considerable variation amongst drugs used for induction, 
maintenance and emergence. As mentioned earlier, randomization did account for such 
variability, as anesthetic technique did not differ significantly between groups.  This makes the 
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study more clinically robust than one employing a strict anesthetic protocol, as it more closely 
approximates real-world conditions.  
 
The use of analgesics, specifically opioid medications have also been associated with 
increased incidence of POV(Apfel et al., 2012; Gan et al., 2014; Wallden et al., 2006). In our 
study, intraoperative administration of morphine was associated with a significantly higher risk 
of POV both immediately in PACU and 24 hrs post discharge (OR = 12.4, 10.5 respectively). In 
contrast, prior studies have suggested that intravenous volume expansion with the administration 
of crystalloid fluids is effective in the prevention of POV (Apfel CC et al., 2012; Elgueta et al., 
2013). Our study results are in accord with those results, showing that patients who received 
>200mL were less likely to vomit while there was no statistically significant difference in the 
amount of fluid delivered to participants in each of the groups.  
 
Another important finding was the effect of dextrose administration in the intervention 
group. The total amount of dextrose received by the participants after administering D5NS as the 
treatment solution was calculated as a mean of 3.46 g and a median of 3.28 g. As expected, there 
was a statistically significant difference in blood glucose levels between groups with the median 
and mean levels in the intervention group being 0.8 mmol/L higher than the active control. It is 
interesting to note that the blood glucose levels did not consistently correlate directly with the 
amount of dextrose received as shown previously. Furthermore, the difference in glucose levels 
between groups was not clinically significant as majority of values varied within normal value 
ranges as presented in table 16 (Pinhas-Hamiel O., 2007). These findings lead us to corroborate 
the safety profile of the intravenous solution used in the study.  
 
The main effect observed after using dextrose based hypertonic solutions is the transient 
increase of the intravascular circulating volume due to rapid metabolism of dextrose; this effect 
has not been found to cause any significant hemodynamic changes  (Hahn & Ljunggren, 2013; 
Sjostrand et al., 2001). Dextrose containing solutions are frequently used in pediatric patients to 
prevent hypoglycemia and dehydration during fasting periods as standard maintenance solution.    
  
Studies have look at the safe amount of fluids to be administered in pediatric patients, 
showing that the maximum infusion rate of fluids containing glucose should not exceed an 
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infusion rate of 4-6 mg/kg/min (which represents the basic glucose utilization in most pediatric 
patients), in order to avoid potential complications including electrolyte imbalance and 
dehydration secondary to increased diuresis  (Leelanukrom & Cunliffe, 2000; Pinhas-Hamiel O., 
2007; van Veen et al., 2011). Our study protocol used a dextrose infusion rate far below this 
recommended rate (2 – 3.5 mg/kg/min depending on patient weight and the length of the 
procedure).  These findings along with the extensive in-hospital experience using dextrose 
containing solutions in children including D5NS, the solution used in the present study, represent 
little or no additional risk to the patient population  (Pinhas-Hamiel O., 2007; Dubois, Gouyet, 
Murat, & Saint-Maurice, 1992).  
 
Several mechanisms of action for intravenous dextrose in the prevention of PONV have 
been postulated by different authors. One theory hypothesizes that dextrose affects motility 
within the gastrointestinal tract by creating an elevated osmotic pressure on the bowel wall, 
reducing the muscle contraction and in turn reducing gastric motility and nausea and vomiting  
(Koivuranta, Laara, Snare, & Alahuhta, 1997). Previous studies have demonstrated the likely pro-
emetic effect that reduced gastric motility has on the perioperative population  (Holtmann & 
Talley, 2014; Lang, 1990), making this theory less plausible. Another theory is based on the 
presumed effect seen after the use of intravenous dextrose for the rehydration of children with 
acute gastroenteritis. The authors postulate the lack of carbohydrate intake secondary to persistent 
nausea and emesis leads to free fatty acid breakdown, ketone surplus, and a subsequent nausea 
and vomiting cycle  (Reid & Losek, 2009). Additionally, studies have shown that children 
develop more rapid and higher concentrations of total ketone bodies compared to adults over the 
initial 6 to 30 hours of fasting (Bonnefont et al., 1990; Fukao et al., 2014; Leelanukrom & 
Cunliffe, 2000b; Sjostrand et al., 2001). The administration of intravenous dextrose would, in 
theory, stimulate insulin release, reduce free fatty acid breakdown, reduce ketosis and in turn 
reduce nausea and vomiting. (Levy & Bachur, 2007) Although the pediatric ambulatory surgical 
population is not likely to be acutely ill with gastrointestinal disease, they are fasted with a 
reduced carbohydrate intake in the preoperative period. The preoperative administration of 
simple sugar may reverse this process, suggesting this to be an underlying possible mechanism of 
action, translated in the results published in prior studies with similar POV incidence, decreased 
use of postoperative antiemetic medications and improvement in postoperative patient recovery 
(Dabu-Bondoc et al., 2013; Hausel et al., 2005; Patel et al., 2013; Yildiz et al., 2013).  
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5.3 Study Limitations  
 
The present study has several limitations. The study population included participants with 
significant risk of POV, given that the age of the participants were children over the age of 3, 
based on the modified risk factor score (L. Eberhart et al., 2004). Excluding patients with other 
potential risk factors including previous personal or family history of POV gave us a standardized 
population, but potentially eliminated the possibility of assessing a further effect of the 
intervention treatment, such as patients with increased POV risk.  The co-administration of the 
well-studied antiemetic medication dexamethasone, made it impossible to establish if the effect 
seen in the results discussed above were due to intravenous dextrose alone  (Bernardo WM & 
Aires FT, 2013; de Orange, Marques, Flores, & Borges, 2012). As discussed previously, 
childhood is a risk factor for increased incidence of POV on its own. Excluding pediatric patients 
from using antiemetic medications or at least two agents as per guidelines, posed ethical 
considerations that prevented us from including another arms in the study in order to compare the 
combined treatment with single interventions and with placebo.  
 
Another limitation included the addition of postoperative nausea for the analysis of 
measurable outcomes, as previously seen in studies assessing the incidence of PONV (Apfel, 
Roewer, & Kortilla, 2002). The initial study protocol included the incidence of postoperative 
nausea as one of the secondary outcomes. Despite having a severity of nausea scoring system that 
has been validated in pediatric cancer patients undergoing chemotherapy over 7 years of age, we 
were not able to apply the scale to our patient population. Most of our study population was 
younger than 7 years of age, with a median age of 4.5 and 4.6 years in the intervention and 
control group respectively. In an attempt to apply this validated scale in the older participants, the 
underlying effect of the general anesthesia and the nature of the procedure, made patients quite 
irritable and unwilling to cooperate with the implementation of the system. For this reason, this 
scale could not be applied in the specific study population. Therefore, the common post-operative 
complication of nausea without vomiting may have been prevalent and could have been 
significantly different between both groups.  
 
It is difficult to determine the impact of the actual dental procedure on the occurrence of 
vomiting, as there is not a clear relationship between the two events. This can be seen as another 
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study limitation. Publications showing the impact of anesthetic medications on patients 
undergoing surgical and non-surgical procedures, may lead to the assumption that it is the effect 
of anesthetic medications, specifically inhaled anesthetics, that has a major impact on the 
occurrence of POV, more so than the procedure itself  (Apfel et al., 2002; Ortiz et al., 2014). 
Although many factors are associated in our study population including their young age, the 
length of exposure to these agents had a stronger association. Different publications in patients 
undergoing non-surgical procedures demonstrated the incidence of vomiting after those 
procedures to be lower to those undergoing surgical procedures under general anesthetic, with an 
incidence of 1.3%   (S. Malviya 2000, National Clinical Guideline Centre, 2010). This could be 
related also to the lower amount of medications used for sedation compared to the actual general 
anesthetic, although specific analysis and comparison for the incidence of PONV was not 
performed, instead an overall incidence of medication related adverse effects (S.  Malviya 2000, 
National Clinical Guideline Centre, 2010).   
 
Finally, the lack of standardize anesthetic protocol could account for an unknown possible 
bias in the study, although randomization was used to minimize this possibility. Additionally, 
anesthesiologist participation was an important part for the conduction of the study.  Two major 
study protocol aspects led to three of the anaesthesiologists not participating in the study. This 
included concerns of the potential adverse effects of the standardized dexamethasone dose and 
the additional work that the study could have added to their daily routine. In order to minimize 
the concerns regarding dexamethasone, an exhaustive literature review was conducted as showed 
previously in the respective section, and an education effort was made to all potential 
participating anaesthesiologists highlighting the safety profile of this intervention  (Bernardo 
WM & Aires FT, 2013; de Orange et al., 2012). Additionally, as mentioned in the methods 
section, minor modifications to the study protocol were done during the conduct of the study, in 
order to minimize the anesthesiologist work without compromising the nature of the study. These 
modifications included the involvement of the researchers in the setting of infusion pumps and 
the measurement of the blood glucose levels at the end of each procedure. Despite these potential 
concerns, anaesthesiologists participation was superb, without which the conduction of the study 
would have been impossible.     
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5.4 Future Directions 
 
While our findings failed to demonstrate that dextrose administration in combination with 
dexamethasone is non-inferior to ondansetron in combination with dexamethasone in the 
reduction of the proportion of POV, many questions remain. Given the relatively low rate of 
POV in our study population, it may be useful to apply this intervention to a pediatric population 
at a higher inherent risk of POV as discussed previously.  
 
In order to expand on the impact of D5NS in the prevention of POV another possible 
future research would include performing an RCT comparing Dexamethasone + Ondansetron as 
standard therapy vs Dexamethasone + Ondansetron + D5NS for the intervention group. We are 
aware of the limitation of comparing each medication separate for ethical reasons explained 
earlier but adding another possible antiemetic to the current treatment of choice may enhance the 
effect of the standard combination.  
 
 
5.5 Conclusions 
 
Returning to the hypothesis posed at the beginning of the study, the results of the 
administration of dextrose containing solutions, specifically D5NS combined with 
dexamethasone compared to ondansetron combined with dexamethasone in preventing POV in 
surgical pediatric patients are inconclusive.  
  
 
Some of the more significant findings to emerge from this study are the protective effect 
of IV fluids and of the administration of propofol as TIVA for the induction and maintenance of 
general anesthetic in the prevention of POV in this population. On the other hand, lengthier 
procedures and the perioperative use of opioids and nitrous oxide were associated with increased 
incidence of POV. These results are in congruence with the results published in the literature.  
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